Page last updated: 2024-12-06

desogestrel

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Desogestrel: A synthetic progestational hormone used often as the progestogenic component of combined oral contraceptive agents (ORAL CONTRACEPTIVES, COMBINED). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID40973
CHEMBL ID1533
CHEBI ID4453
SCHEMBL ID41341
MeSH IDM0026028

Synonyms (93)

Synonym
AC-308
cerazette
org-2969
(17alpha)-13-ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol
LMST02030104
13-ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17alpha-ol
desogestrelum [inn-latin]
hsdb 3593
mircette
einecs 258-929-4
desogen
18,19-dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17alpha)-
org 2969
17alpha-ethynyl-11-methylidene-18a-homo-estr-4-en-17beta-ol
CHEBI:4453 ,
desogestrelum
C07629
desogestrel
54024-22-5
DB00304
13-ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol
desogestrel (usan/inn)
D02367
NCGC00167449-01
CHEMBL1533
(8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
D4163
dtxcid702898
dtxsid6022898 ,
cas-54024-22-5
tox21_112453
S4638 ,
AKOS015963198
81k9v7m3a3 ,
unii-81k9v7m3a3
desogestrel [usan:inn:ban]
ortho-cept component desogestrel
desogestrel [usp-rs]
desogestrel component of ortho-cept
desogestrel [who-dd]
desogestrel component of kariva
desogestrel [orange book]
desogestrel [mart.]
desogen component desogestrel
desogestrel component of cyclessa
desogestrel [jan]
desogestrel [ep monograph]
viorele component desogestrel
bekyree component desogestrel
kariva component desogestrel
desogestrel [usp monograph]
desogestrel component of velivet
velivet component desogestrel
mircette component desogestrel
desogestrel component of mircette
desogestrel [hsdb]
desogestrel [inn]
volnea component desogestrel
desogestrel [usan]
enskyce component desogestrel
pimtrea component desogestrel
13-ethyl-11-methylene-18,19-dinor-17a-pregn-4-en-20-yn-17-ol
desogestrel [mi]
desogestrel [vandf]
desogestrel component of desogen
isibloom component desogestrel
cyclessa component desogestrel
gtpl7065
bdbm50423510
SCHEMBL41341
RPLCPCMSCLEKRS-BPIQYHPVSA-N
CS-3686
17alpha-ethynyl-13beta-ethyl-11-methylene-4-gonen-17-ol
desogestrel, british pharmacopoeia (bp) reference standard
HY-12516
J-520217
SR-01000883959-1
sr-01000883959
SR-01000883959-2
desogestrel, vetranal(tm), analytical standard
desogestrel, united states pharmacopeia (usp) reference standard
desogestrel, pharmaceutical secondary standard; certified reference material
desogestrel, european pharmacopoeia (ep) reference standard
desogestrel for system suitability, european pharmacopoeia (ep) reference standard
BCP18794
Q415304
mfcd00869346
AS-13022
CCG-267585
desogestrel 100 microg/ml in acetonitrile
C15951
EN300-23839418
(1r,3as,3bs,9ar,9bs,11as)-11a-ethyl-1-ethynyl-10-methylidene-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-ol

Research Excerpts

Overview

Desogestrel (DSG) is a third-generation 19-nortestosterone derivative progestogen. At doses used for oral contraception, it is devoid of any androgenic activity.

ExcerptReferenceRelevance
"Oral desogestrel is a cheap, easily available, safe, and quite efficient alternative for endometrial preparation before hysteroscopic procedures."( Oral Desogestrel as Endometrial Preparation before Operative Hysteroscopy: A Systematic Review.
Alonso Pacheco, L; Carugno, J; Ciebiera, M; Laganà, AS; Sierant, A; Vitale, SG; Zgliczyńska, M; Zgliczyński, S, 2021
)
1.59
"Desogestrel (DSG) is a third-generation progestin. "( Drug safety evaluation of desogestrel.
Ferrero, S; Leone Roberti Maggiore, U; Remorgida, V; Scala, C; Venturini, PL, 2013
)
2.13
"Desogestrel (DSG) is a third-generation 19-nortestosterone derivative progestogen. "( Pharmacokinetic evaluation of desogestrel as a female contraceptive.
Cagnacci, A; Grandi, G; Volpe, A, 2014
)
2.13
"Desogestrel is a potent progestogen, which, at the doses used for oral contraception, is devoid of any androgenic activity."( Clinical trial of an oral contraceptive containing desogestrel and ethinyl estradiol.
Weijers, MJ, 1982
)
1.24
"Desogestrel is a highly selective gonane progestin. "( Clinical and metabolic features of desogestrel: a new oral contraceptive preparation.
Archer, DF, 1994
)
2.01
"Desogestrel is a strong progestogen with low androgenicity which has so far been used only in oral contraceptives. "( A novel oestradiol--desogestrel preparation for hormone replacement therapy: effects on hormones, lipids, bone, climacteric symptoms and endometrium.
Hirvonen, E; Saure, A; Tikkanen, MJ; Viinikka, L; Ylikorkala, O, 1993
)
2.05
"Desogestrel is a gonane progestogen that in early studies had an improved ratio between desired progestational effects and undesired androgenic effects. "( Lipid metabolism effects with desogestrel-containing oral contraceptives.
Burkman, RT, 1993
)
2.02
"Desogestrel is a gonane progestogen that is rapidly metabolized to 3-keto-desogestrel, the metabolite believed to be exclusively responsible for the progestational effects of desogestrel after oral administration. "( Lipid metabolism effects with desogestrel-containing oral contraceptives.
Burkman, RT, 1993
)
2.02
"Desogestrel is a new, potent progestogen with very low androgenic properties. "( Desogestrel.
Stone, SC, 1995
)
3.18
"Desogestrel is a 3-deoxo progestogenic steroid that requires bioactivation to 3-ketodesogestrel. "( The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
Back, DJ; Gentile, DM; Shimada, T; Verhoeven, CH, 1998
)
1.97
"Desogestrel is a 3-deoxy progestogenic oral contraceptive steroid which requires bioactivation to 3-ketodesogestrel. "( The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
Back, DJ; Gentile, DM; Shimada, T; Verhoeven, CH, 1998
)
1.97
"Desogestrel (DSG) is a less-androgenic progestogen than levonorgestrel (LNG). "( Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel.
Broyles, FE; Chandler, WL; Cheung, M; Knopp, RH; Marcovina, S; Moore, K, 2001
)
1.97
"Desogestrel is a prohormone that must first be metabolized into its biologically active form."( The new era in oral contraception: pills containing gestodene, norgestimate, and desogestrel.
London, RS, 1992
)
1.23

Effects

Desogestrel 75 mg has a 12-h missed-pill window; however, its poor cycle control limits a more common use.

Desogestrel has a long half-life (23.8 hours) which prolongs the period during which women who miss 1-2 pills can be protected from pregnancy.

ExcerptReferenceRelevance
"Desogestrel 75 mg has a 12-h missed-pill window; however, its poor cycle control limits a more common use."( A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg.
Colli, E; Palacios, S; Regidor, PA, 2019
)
1.44
"Desogestrel has a long half-life (23.8 hours) which prolongs the period during which women who miss 1-2 pills can be protected from pregnancy."( Clinical review of a monophasic oral contraceptive containing desogestrel and ethinyl estradiol.
Stone, S, 1993
)
1.25
"Desogestrel 75 mg has a 12-h missed-pill window; however, its poor cycle control limits a more common use."( A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg.
Colli, E; Palacios, S; Regidor, PA, 2019
)
1.44
"Desogestrel has a long half-life (23.8 hours) which prolongs the period during which women who miss 1-2 pills can be protected from pregnancy."( Clinical review of a monophasic oral contraceptive containing desogestrel and ethinyl estradiol.
Stone, S, 1993
)
1.25
"Desogestrel has been found to be among the strongest suppressors of ovarian activity."( Contraceptive efficacy of a monophasic oral contraceptive containing desogestrel.
Corson, SL, 1993
)
1.24
"Desogestrel has been demonstrated to have generally less pronounced effects on these parameters of carbohydrate metabolism."( Effects of desogestrel on carbohydrate metabolism.
Shoupe, D, 1993
)
1.3
"Desogestrel have been evaluated in 17 non-obese hirsute women, with normal serum LH and FSH values and their ratio, and evidence for Micropolycystic Ovary Syndrome (MPCO) on ultrasound examination."( Short-term treatment of hirsutism related to micropolycystic ovary syndrome with a combination type oral contraceptive containing desogestrel.
Arena, D; D'Arrigo, F; Granata, A; Granese, D; Pullè, C; Sobbrio, GA; Trimarchi, F,
)
1.06

Actions

ExcerptReferenceRelevance
"Desogestrel did not cause any significant changes in HDL or HDL2 cholesterol concentrations, but it reduced the VLDL triglyceride (P less than 0.01) and total serum (P less than 0.05) triglyceride concentrations."( Effects of two progestins with different androgenic properties on hepatic endothelial lipase and high density lipoprotein2.
Kuusi, T; Nikkilä, EA; Sipinen, S; Tikkanen, MJ, 1985
)
0.99

Toxicity

Desogestrel 75 micrograms/day is a reliable and safe progestogen-only pill with a contraceptive efficacy superior to levonorgestrel 30 microgram's/day. The frequency and pattern of adverse experiences were comparable for desogstrel 75micrograms / day and levonorgestrel 20microgram / day. To detect the signals for drospirenone-containing oral contraceptives (DCOCs) and describe the reporting patterns of adverse events.

ExcerptReferenceRelevance
" The study medication demonstrated no adverse effects on cervical cytology, blood pressure, body weight or laboratory variables, while pre-existing benign breast disease generally improved."( A multicenter efficacy and safety study of an oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol.
Walling, M, 1992
)
0.5
" The study medication demonstrated no adverse effects on cervical cytology, blood pressure, body weight or laboratory variables, while pre-existing benign breast disease generally improved."( A multicenter efficacy and safety study of an oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol.
Walling, M, 1992
)
0.5
"6% of the subjects discontinued treatment because of drug-related adverse events."( Contraceptive efficacy and safety of a monophasic oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol: United States clinical experience using a "Sunday start" approach.
Notelovitz, M, 1995
)
0.51
" The side effect profile was favourable."( Cycle control and side effects of a new combiphasic oral contraceptive regimen.
Coelingh Bennink, HJ; Dieben, TO; op ten Berg, MT, 1994
)
0.29
" These findings show that the new OC has very good cycle control and a agreeable side effect profile."( Cycle control and side effects of a new combiphasic oral contraceptive regimen.
Coelingh Bennink, HJ; Dieben, TO; op ten Berg, MT, 1994
)
0.29
" Our results indicate that the tested new biphasic OC combination is reliable, well tolerated, safe and effective against hyperandrogenism."( Efficacy on hyperandrogenism and safety of a new oral contraceptive biphasic formulation containing desogestrel.
Angioni, S; Deiana, P; Genazzani, AR; Grasso, A; Mauri, A; Silferi, M; Volpe, A, 1994
)
0.5
"To compare two oral contraceptive pills, both containing 150 micrograms desogestrel, but with either 20 micrograms (Mercilon) or 30 micrograms (Marvelon/Desolett) ethinyl oestradiol (EE), regarding reliability, cycle control and side effect profile."( Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
Akerlund, M; Røde, A; Westergaard, J, 1993
)
0.72
"No serious adverse effects were observed in either group."( A triphasic oral contraceptive pill, CTR-05: clinical efficacy and safety.
Ledger, WJ; Saxena, BB; Singh, M; Singh, R; Thomas, D, 1996
)
0.29
"6% of all subjects reported one or more adverse events, and a total of 43."( An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. The Mircette Study Group.
, 1998
)
0.3
"The study confirmed that Mircette is a safe and efficacious oral contraceptive that is well tolerated and acceptable to women who have previously used oral contraceptives, as well as first-time users."( An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. The Mircette Study Group.
, 1998
)
0.3
" The most common drug-related adverse event was headache (7%)."( A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand.
Bennink, HJ; Kiriwat, O; Koetsawang, S; Korver, T; Patanayindee, A, 1998
)
0.3
" The frequency and pattern of adverse experiences were comparable for desogestrel 75 micrograms/day and levonorgestrel 30 micrograms/day."( A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Collaborative Study Group on the Desogestrel-containing Progest
, 1998
)
0.74
"Desogestrel 75 micrograms/day is a reliable and safe progestogen-only pill with a contraceptive efficacy superior to levonorgestrel 30 micrograms/day."( A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Collaborative Study Group on the Desogestrel-containing Progest
, 1998
)
1.95
"This integrated analysis evaluates nonmenstrual adverse events, blood pressure, and body weight changes during the use of the single-rod etonogestrel-containing contraceptive implant, Implanon; these aspects are compared for Implanon and Norplant, the six-capsule implant containing levonorgestrel."( An integrated analysis of nonmenstrual adverse events with Implanon.
Urbancsek, J, 1998
)
0.3
"2%) and adverse experiences in the third year (3."( A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group.
Coelingh Bennink, H; Croxatto, HB; Massai, R; Urbancsek, J; van Beek, A, 1999
)
0.3
" The incidence of other adverse events was similar among treatment groups, an observation that supports the safety of both formulations."( Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial.
Kaunitz, AM, 2000
)
0.53
" Progestins with androgenic properties have been incriminated in unexpected vascular events because of their adverse effect on the lipid profile."( [Side effects of third generation progestagens].
Sitruk-ware, R, 1993
)
0.29
" Safety was assessed through adverse experiences (AEs), laboratory tests and physical and gynecologic examinations."( Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel.
Archer, DF; Funk, S; Miller, MM; Mishell, DR; Poindexter, A; Schmidt, J; Zampaglione, E, 2005
)
0.33
"To determine adverse events and discontinuation of Implanon in healthy Thai women between 16 and 45 years of age."( One year study of Implanon on the adverse events and discontinuation.
Chaovisitsaree, S; Morakote, N; Noium, S; Piyamongkol, W; Pongsatha, S; Soonthornlimsiri, N, 2005
)
0.33
"Determination of adverse events was done three months after Implanon insertion."( One year study of Implanon on the adverse events and discontinuation.
Chaovisitsaree, S; Morakote, N; Noium, S; Piyamongkol, W; Pongsatha, S; Soonthornlimsiri, N, 2005
)
0.33
"1%) were the most menstrual adverse events."( One year study of Implanon on the adverse events and discontinuation.
Chaovisitsaree, S; Morakote, N; Noium, S; Piyamongkol, W; Pongsatha, S; Soonthornlimsiri, N, 2005
)
0.33
" It produced similar adverse events like other progestin-only contraceptives."( One year study of Implanon on the adverse events and discontinuation.
Chaovisitsaree, S; Morakote, N; Noium, S; Piyamongkol, W; Pongsatha, S; Soonthornlimsiri, N, 2005
)
0.33
" Adverse events were generally of mild-to-moderate intensity and were those typical of hormonal contraceptive use."( A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20mug and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20mug and desogestrel 150mug.
Gruber, DM; Huber, JC; Marr, J; Melis, GB; Parke, S; Stagg, C, 2006
)
0.53
"evaluation of the frequency of adverse events during the therapy with a transdermal contraceptive system (TCS) in comparison to an oral contraceptive."( [Safety evaluation of a transdermal contraceptive system with an oral contraceptive].
Radowicki, S; Skórzewska, K; Szlendak, K, 2005
)
0.33
" Safety evaluation was based on the frequency of adverse effects, changes in physical and gynecological examinations."( [Safety evaluation of a transdermal contraceptive system with an oral contraceptive].
Radowicki, S; Skórzewska, K; Szlendak, K, 2005
)
0.33
"The incidence of most adverse effects was similar between the transdermal and oral contraceptive therapies, except of a higher incidence of breast pain, dysmenorrhoea and application site reactions in the patch group."( [Safety evaluation of a transdermal contraceptive system with an oral contraceptive].
Radowicki, S; Skórzewska, K; Szlendak, K, 2005
)
0.33
"The study suggests that a transdermal contraceptive system is a safe and well tolerated therapy."( [Safety evaluation of a transdermal contraceptive system with an oral contraceptive].
Radowicki, S; Skórzewska, K; Szlendak, K, 2005
)
0.33
"The analysis of adverse events revealed two crucial points for acceptability, compliance and continuation: poor cycle control and disturbance of sexual intercourse due to vaginal dryness and loss of desire."( Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives.
Cagiano, R; Sabatini, R, 2006
)
0.33
" Assessments included reports of adverse events (AEs), reasons and rates of discontinuation, insertion/removal complications, and the condition of the implant site."( Tolerability and clinical safety of Implanon.
Blumenthal, PD; Gemzell-Danielsson, K; Marintcheva-Petrova, M, 2008
)
0.35
"7%; the most frequently reported reasons for discontinuation were adverse events (13."( Tolerability and clinical safety of Implanon.
Blumenthal, PD; Gemzell-Danielsson, K; Marintcheva-Petrova, M, 2008
)
0.35
"Implanon is a well-tolerated and safe method of long-acting hormonal contraception for women."( Tolerability and clinical safety of Implanon.
Blumenthal, PD; Gemzell-Danielsson, K; Marintcheva-Petrova, M, 2008
)
0.35
"96% women presented one or more adverse effects during the follow-up; 33."( Long-term safety and tolerability of flutamide for the treatment of hirsutism.
Balasch, J; Castelo-Branco, C; Gómez, O; Moyano, D, 2009
)
0.35
"Flutamide is very effective for hirsutism treatment; however, adverse effects are very frequent and associated with low long-term compliance."( Long-term safety and tolerability of flutamide for the treatment of hirsutism.
Balasch, J; Castelo-Branco, C; Gómez, O; Moyano, D, 2009
)
0.35
" Safety was primarily assessed by incidence of adverse events."( Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials.
Darney, P; Kaunitz, AM; Patel, A; Rosen, K; Shapiro, LS, 2009
)
0.35
" Common drug-related adverse events were headache, weight gain, acne, breast tenderness, emotional lability, and abdominal pain."( Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials.
Darney, P; Kaunitz, AM; Patel, A; Rosen, K; Shapiro, LS, 2009
)
0.35
"The ENG implant is an efficacious and safe method of contraception which does not require patients' consistent action."( Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials.
Darney, P; Kaunitz, AM; Patel, A; Rosen, K; Shapiro, LS, 2009
)
0.35
"This low-dose, 28-day OC incorporating 7 days of 10 mcg EE during the hormone free interval is effective and safe for the prevention of pregnancy and is well-tolerated by women."( Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo.
Hait, H; Poindexter, A; Reape, KZ, 2008
)
0.35
"Implanon was an effective, safe and acceptable method of contraception amongst its acceptors."( Safety, efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital.
Aisien, AO; Enosolease, ME, 2010
)
0.36
" Overall low rates of adverse effects such as pain, bleeding, infection and perforation, are documented to occur in all studies regardless of the timing or route of IUC insertion."( Immediate post-partum initiation of intrauterine contraception and implants: a review of the safety and guidelines for use.
Black, KI; Mwalwanda, CS, 2013
)
0.39
"It was safe and efficacy that GnRH-a combined with laparoscopic conservative surgery were used in treatment of endometriosis."( [Efficacy and safety of GnRH-a combine with laparoscope conservative surgery in the treatment of the moderate or severe endometriosis].
Cheng, J; Lü, QY; Zeng, KK; Zhang, W; Zhang, WT; Zhong, YJ, 2013
)
0.39
" Safety and tolerability were assessed primarily through reported adverse events (AEs)."( Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol.
Ackerman, R; Feldman, R; Howard, B; Hsieh, J; Kroll, R; Ricciotti, N; Weiss, H, 2016
)
0.43
"3% (fingers-only) of subjects reported at least 1 treatment-related adverse event (AE); all were mild."( Safety and efficacy of the NuvaRing® Applicator in healthy females: a multicenter, open-label, randomized, 2-period crossover study.
Feldman, R; Fox, MC; Frenkl, TL; Wang, Y; Yacik, C, 2016
)
0.43
"Once-monthly NuvaRing is efficacious and safe for use in Chinese women."( Efficacy and safety of the contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive in Chinese women: a 1-year randomised trial.
Chang, Q; Di, W; Fan, GS; Korver, T; Marintcheva-Petrova, M; McCrary Sisk, C; Qin, Y; Ren, M; Su, P; Wang, G; Wu, S; Yacik, C, 2016
)
0.43
"The objective was to determine the association between use of intrauterine devices (IUDs) by young women and risk of adverse outcomes."( The safety of intrauterine devices among young women: a systematic review.
Curtis, KM; Jatlaoui, TC; Riley, HEM, 2017
)
0.46
"Overall evidence suggests that the risk of adverse outcomes related to pregnancy, perforation, infection, heavy bleeding or removals for bleeding among young IUD users is low and may not be clinically meaningful."( The safety of intrauterine devices among young women: a systematic review.
Curtis, KM; Jatlaoui, TC; Riley, HEM, 2017
)
0.46
" The aim of this study was to evaluate the incidence of TE using the Japanese Adverse Drug Event Report (JADER) database."( Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.
Abe, J; Fukuda, A; Hane, Y; Hasegawa, S; Hatahira, H; Hirade, K; Kinosada, Y; Matsui, T; Motooka, Y; Naganuma, M; Nakamura, M; Sasaoka, S; Takahashi, Y, 2017
)
0.46
"3%) and discomfort due to bleeding alterations and other adverse effects (25."( Influence of age on tolerability, safety and effectiveness of subdermal contraceptive implants.
Castillo Cañadas, AM; García Santos, F; Gómez García, MT; González de Merlo, G; González Mirasol, E; López Del Cerro, E; Serrano Diana, C, 2018
)
0.48
" There were no incident pregnancies, serious adverse events, serious social harms, or early discontinuations for safety reasons."( A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use.
Agaba, S; Buyze, J; Crucitti, T; De Baetselier, I; Delvaux, T; Jespers, V; Kestelyn, E; Mwambarangwe, L; Ndagijimana, JC; Umulisa, MM; Uwineza, M; van de Wijgert, JHHM; Van Nuil, JI, 2018
)
0.48
"Intermittent and continuous NuvaRing® use were safe in Rwandan women and improved Nugent scores over time."( A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use.
Agaba, S; Buyze, J; Crucitti, T; De Baetselier, I; Delvaux, T; Jespers, V; Kestelyn, E; Mwambarangwe, L; Ndagijimana, JC; Umulisa, MM; Uwineza, M; van de Wijgert, JHHM; Van Nuil, JI, 2018
)
0.48
" A minority of respondents correctly classified the progestin-only pill, depot medroxyprogesterone acetate, the etonogestrel implant, the levonorgestrel intrauterine system and the copper intrauterine device as safe to use during lactation [14/56 (25%), 24/56 (43%), 27/56 (48%), 19/55 (35%) and 9/55 (16%), respectively]."( An exploratory study of the perception of contraceptive safety and impact on lactation among postpartum nurses at Women and Infants Hospital in 2017.
Allen, RH; Cohen, KE; Has, P; Matteson, KA, 2019
)
0.51
"To examine the safety and risk association between hormonal contraceptive desogestrel among women with psychiatric disorders using adverse drug reaction database of FDA Adverse Events Reporting System (FAERS) and EudraVigilance (EV)."( Desogestrel and Severe Psychiatric Disorders: A Retrospective Analysis of Federal Adverse Event Reporting System and EudraVigilance.
Kothari, C; Shah, M, 2021
)
2.29
" Food and Drug Administration's Adverse Event Reporting System by couse of CYP3A4-inducing drugs and route of administration for levonorgestrel and etonogestrel/desogestrel."( Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system.
Brown, J; Cicali, B; Schmidt, S; Sunaga, T, 2021
)
0.82
" This study provides evidence from an Adverse Event Reporting System that CYP3A4-inducing medications increase the risk of unintended pregnancy for oral and implant contraceptives but not intrauterine or vaginal devices."( Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system.
Brown, J; Cicali, B; Schmidt, S; Sunaga, T, 2021
)
0.62
" We also evaluated implant-related side effect profiles and continuation rates among cases only."( Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients.
Lazorwitz, A; Lew, J; Sheeder, J, 2021
)
0.62
" When compared to age and transplant organ-matched controls, contraceptive implant users were not at increased risk for adverse transplant-related outcomes."( Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients.
Lazorwitz, A; Lew, J; Sheeder, J, 2021
)
0.62
"This study provides the first data that the etonogestrel contraceptive implant is likely a safe contraceptive option for reproductive-age women who are solid organ transplant recipients."( Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients.
Lazorwitz, A; Lew, J; Sheeder, J, 2021
)
0.62
" The etonogestrel contraceptive implant remains a safe and effective method of contraception for this specific population, with no increase in graft-related complications among contraceptive implant users."( Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients.
Lazorwitz, A; Lew, J; Sheeder, J, 2021
)
0.62
"To detect the signals for drospirenone-containing oral contraceptives (DCOCs) and describe the reporting pattern of adverse events (AEs) caused by DCOCs compared with levonorgestrel/desogestrel/gestodene-containing (second/third generation) oral contraceptives."( Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008-2017.
Choe, SA; Choi, A; Jeon, HL; Lee, Y; Noh, Y; Shin, JY, 2021
)
0.81
"The Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System Database from 1 February 2008 to 31 December 2017."( Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008-2017.
Choe, SA; Choi, A; Jeon, HL; Lee, Y; Noh, Y; Shin, JY, 2021
)
0.62
" Additionally, we found higher reports of the deaths and vascular AEs associated with DCOCs than with second/third generation oral contraceptives, which warrants careful monitoring to ensure the safe use of DCOCs."( Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008-2017.
Choe, SA; Choi, A; Jeon, HL; Lee, Y; Noh, Y; Shin, JY, 2021
)
0.62

Pharmacokinetics

The pharmacodynamic effects of a new type of 3-keto-Desogestrel [3kDOG] releasing vaginal ring was studied in a group of 20 normally ovulating women during a period of 21 days continuous use. Basic pharmacokinetic parameters, like Cmax, tmax and AUC, were determined on days 1, 10 and 21 of the first and the third treatment cycle, respectively.

ExcerptReferenceRelevance
" Basic pharmacokinetic parameters, like Cmax, tmax and AUC, as well as the serum protein binding of 3-keto-desogestrel were determined on days 1, 10 and 21 of the first and the third treatment cycle, respectively."( Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive.
al-Yacoub, G; Back, DJ; Jütting, G; Kuhnz, W; Ormesher, SE; Power, J, 1992
)
0.75
" The results on serum protein binding of KDG can help researchers interpret overall pharmacokinetic changes."( Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive.
al-Yacoub, G; Back, DJ; Jütting, G; Kuhnz, W; Ormesher, SE; Power, J, 1992
)
0.53
" Goethe University in Frankfurt am Main, Germany, compared serum data on 34 20-39 year old women who used either the oral contraceptive Marvelon (30 mcg ethinyl estradiol [EE] and 150 mcg desogestrel [DG] or Lovelle (20 mcg EE and 150 mcg DG) to observe their pharmacokinetics and some pharmacodynamic parameters."( Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
Fitzner, M; Jung-Hoffmann, C; Kuhl, H, 1991
)
0.69
" These differences in serum concentrations are determined by the different pharmacokinetic behaviour of the gestagens, which in turn is largely determined by their binding to serum proteins."( Potency and pharmacokinetics of gestagens.
Fotherby, K, 1990
)
0.28
" The pharmacokinetic properties of desogestrel were characterized by the following parameters: (1) maximum serum concentration, (2) time to maximum serum concentration, (3) total area under the serum concentration versus time curve, and (4) serum half-life of elimination."( Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
Assendorp, R; Bergink, W; Kloosterboer, L; Qvist, I; van Lier, W; Voortman, G, 1990
)
0.81
" The pharmacokinetic properties of desogestrel were characterized by the following parameters: maximum serum concentration, time to maximum serum concentration, total area under the serum concentration vs time curve, and serum 1/2 life of elimination."( Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
Assendorp, R; Bergink, W; Kloosterboer, L; Qvist, I; van Lier, W; Voortman, G, 1990
)
0.81
"The pharmacodynamic effects of a new type of 3-keto-Desogestrel [3kDOG] releasing vaginal ring was studied in a group of 20 normally ovulating women during a period of 21 days continuous use."( Pharmacodynamics of a contraceptive vaginal ring releasing 3-keto-desogestrel.
Jackson, R; Newton, JR, 1989
)
0.76
"To demonstrate that pharmacokinetic measurements were made at steady state."( Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol.
Archer, DF; Lammers, P; Timmer, CJ, 1994
)
0.53
" The statistical analysis on Cmax, AUC, Css,min, and Tmax indicated that the pharmacokinetics of ethinyl E2 on days 7, 14, and 21 were not statistically significantly different, indicating dose equivalency."( Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol.
Archer, DF; Lammers, P; Timmer, CJ, 1994
)
0.53
" After micronized 17 beta-oestradiol however, there was a 2-3-fold increase in the ratio at Cmax and slower elimination of 17 beta-oestradiol from plasma, which may be due to the fact that high serum oestrone levels may serve as a reservoir, since both a metabolite and also a precursor of 17 beta-oestradiol."( Pharmacokinetic evaluation of oral 17 beta-oestradiol and two different fat soluble analogues in ovariectomized women.
Cullberg, G; Hedner, T; Schubert, W, 1993
)
0.29
" The pharmacokinetic parameters of 3-keto-desogestrel are generally comparable with those of levonorgestrel and norethindrone."( Pharmacokinetics of desogestrel.
Adashi, EY; McClamrock, HD, 1993
)
0.87
" The pharmacokinetic parameters of 3-keto-desogestrel are generally comparable with those of levonorgestrel and norethindrone."( Pharmacokinetics of desogestrel.
Adashi, EY; McClamrock, HD, 1993
)
0.87
" Respective changes were seen with regard to the area under the EE2 serum concentration curve up to 4 and 24 hours (AUC0-4 and AUC0-24), cmax and tmax of serum EE2."( Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
Back, DJ; Daume, E; Hammerstein, J; Neiss, A; Schindler, AE; Simon, A; Ward, S; Winkler, UH, 1993
)
0.58
" No significant differences were seen in serum EE2 levels including the rise in mean EE2 on days 1-10, or the smaller rise between days 10-21, or the pharmacokinetic parameters Cmax, tmax, area under the curve (AUC) at 0-4 hours, or AUC at 0-24 hours."( Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
Back, DJ; Daume, E; Hammerstein, J; Neiss, A; Schindler, AE; Simon, A; Ward, S; Winkler, UH, 1993
)
0.58
"The purpose of the present report is to summarize the most important pharmacokinetic features of the new progestogens."( Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism.
Stanczyk, FZ, 1997
)
0.53
" The maximum serum concentration, Cmax, of the second absorption or recirculation of oestrone was 20% that of the first, and the Cmax of the third circulation was 50% that of the second."( Enterohepatic cycling and pharmacokinetics of oestradiol in postmenopausal women.
Timmer, CJ; Vree, TB, 1998
)
0.3
" The half-life of elimination was 25 hours--significantly lower than the 41."( Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon.
Huber, J; Schnabel, P; van Beek, A; Wenzl, R, 1998
)
0.3
" Maximum mean serum concentrations (Cmax) amounted to 813 pg/mL and the time (tmax) to reach Cmax was 4 days."( Pharmacokinetics of Implanon. An integrated analysis.
Huber, J; Wenzl, R, 1998
)
0.3
"This paper reviews pharmacokinetic and pharmacodynamic studies with Implanon, which provides serum etonogestrel levels sufficient to inhibit ovulation within 8 h of insertion."( The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant.
Bennink, HJ, 2000
)
0.31
"Two pharmacokinetic studies were performed to investigate whether there is any interaction between etonogestrel or ethinylestradiol released from the combined contraceptive vaginal ring NuvaRing and concomitant treatment with orally administered amoxicillin or doxycycline."( Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials.
Dogterom, P; Thomsen, T; van den Heuvel, MW, 2005
)
0.33
" Calculation of etonogestrel and ethinylestradiol interaction/control ratios confirmed the absence of pharmacokinetic interactions."( Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials.
Dogterom, P; Thomsen, T; van den Heuvel, MW, 2005
)
0.33
"The results from these studies demonstrate the absence of pharmacokinetic interactions between etonogestrel and ethinylestradiol released from NuvaRing and the oral antibiotics amoxicillin and doxycycline, suggesting that contraceptive efficacy would also be unaffected."( Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials.
Dogterom, P; Thomsen, T; van den Heuvel, MW, 2005
)
0.33
" Pharmacokinetic data (AUC, C(max), t(max)) were determined the day before (reference) and after (test) a 14-day period of Ze 117 intake (250 mg twice daily)."( St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive.
Bauer, S; Brattström, A; Kunter, U; Roots, I; Will-Shahab, L, 2009
)
0.35
" Etonogestrel concentrations were measured at 50-hour intervals through 300 hours postinsertion, then at 3 and 6 months to establish a pharmacokinetic curve."( Pharmacokinetics of the etonogestrel contraceptive implant in obese women.
Chan, LN; Gilliam, M; Martins, S; Mistretta, S; Mornar, S; Neustadt, A, 2012
)
0.38
" We evaluated the effect of 2 highly active antiretroviral therapy (HAART) regimens (1 including efavirenz and the other ritonavir-boosted lopinavir) on the pharmacokinetic (PK) parameters of an ENG-releasing implant in HIV-positive women."( Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.
Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; de Souza, RM; Duarte, G; Ferriani, RA; Quintana, SM; Rocha Prandini, TR; Scaranari, C; Vieira, CS, 2014
)
0.4
"This was a small, descriptive, pharmacodynamic study in which some findings differed by study site."( A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception.
Abitbol, JL; Brache, V; Cochon, L; Duijkers, IJ; Kapp, N; Klipping, C; Levy, DP; Monteil, C, 2015
)
0.65
"Sparse pharmacokinetic sampling of ENG, NVP, or EFV were performed at screening, entry, and then 1, 4, 12, and 24-week postimplant insertion."( Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.
Achilles, SL; Chappell, CA; Chen, BA; Cohn, SE; Darin, KM; Lamorde, M; Mackline, H; Nakalema, S; Riddler, SA; Scarsi, KK, 2017
)
0.46
"Single centre, open label, phase-2 pharmacokinetic study."( Plasma concentrations of etonogestrel in women using oral desogestrel before and after Roux-en-Y gastric bypass surgery: a pharmacokinetic study.
Ärlemalm, A; Brynhildsen, J; Carlsson, B; Frisk, J; Ginstman, C; Hägg, S, 2019
)
0.76
"Steady-state etonogestrel pharmacokinetic (PK) parameters were measured on three occasions for each individual (at 8 ± 6 weeks before surgery, and at 12 ± 2 and 52 ± 2 weeks after surgery)."( Plasma concentrations of etonogestrel in women using oral desogestrel before and after Roux-en-Y gastric bypass surgery: a pharmacokinetic study.
Ärlemalm, A; Brynhildsen, J; Carlsson, B; Frisk, J; Ginstman, C; Hägg, S, 2019
)
0.76
" Associations between patient genotype and etonogestrel pharmacokinetic parameters were determined through univariate and multivariate linear regression."( Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M, 2019
)
0.51
"Within the control group, CYP2B6 983 T>C was associated with 27% higher etonogestrel Cmax and 28% higher AUC0-24weeks."( Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M, 2019
)
0.51
"We did a parallel, three-group, pharmacokinetic evaluation at HIV clinics in Asia (two sites), South America (five), sub-Saharan Africa (three), and the USA (11) between Dec 30, 2014, and Sept 12, 2016."( Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
Akelo, V; Aweeka, F; Aziz, M; Berzins, B; Cohn, SE; Coombs, RW; Coughlin, K; Cramer, YS; Friedman, RK; Gingrich, D; Godfrey, C; Moran, LE; Rosenkranz, SL; Scarsi, KK; Swaminathan, S; Zorrilla, CD, 2019
)
0.51
" Further studies designed to examine pharmacodynamic endpoints, such as ovulation, when intravaginal ring hormones are combined with efavirenz are warranted."( Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
Akelo, V; Aweeka, F; Aziz, M; Berzins, B; Cohn, SE; Coombs, RW; Coughlin, K; Cramer, YS; Friedman, RK; Gingrich, D; Godfrey, C; Moran, LE; Rosenkranz, SL; Scarsi, KK; Swaminathan, S; Zorrilla, CD, 2019
)
0.51
"We confirm that single-time measurements of serum etonogestrel concentration are acceptable pharmacokinetic outcomes for etonogestrel implant studies."( Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period.
Lazorwitz, A; Sheeder, J; Teal, S, 2022
)
0.72
" Our repeated measures study using modern liquid-chromatography mass-spectrometry analysis methods provides updated support for single-time pharmacokinetic measurements among etonogestrel implant users."( Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period.
Lazorwitz, A; Sheeder, J; Teal, S, 2022
)
0.72
" We aimed to evaluate the pharmacokinetic and pharmacodynamic effects of a short course (2 weeks) of rifampin on serum etonogestrel (ENG) concentrations and serologic measures of ovarian activity (endogenous estradiol [E2] and progesterone [P4]) among ENG implant users."( The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study.
Lazorwitz, A; Sheeder, J; Teal, S, 2023
)
0.91

Compound-Compound Interactions

The combination with drospirenone had less impact on blood pressure than the combination with desogestrel.

ExcerptReferenceRelevance
" The four groups receiving hormone replacement therapy were given 2 mg estradiol valerate equivalents (E), either sequentially combined with 75 micrograms levonorgestrel (E/LNG), 10 mg medroxyprogesterone acetate (E/MPA), or 150 micrograms desogestrel (E/DG), or continuously combined with 1 mg cyproterone acetate (E/CPA)."( Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives.
Christiansen, C; Haarbo, J; Hassager, C; Jensen, SB; Riis, BJ, 1991
)
0.46
" In 60 healthy, randomly allocated women, the effects of ethinyl estradiol, 30 micrograms, combined with gestodene, 75 micrograms, and desogestrel, 150 micrograms, on blood coagulation, fibrinolysis, and platelet function were compared."( Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets.
Bonnar, J; Daly, L, 1990
)
0.71
" In combination with EE, however, DG seems to counteract the effects of EE to a lesser extent than NORG, as judged particularly from the effects on TG and PL in serum and VLDL."( The effects of two gonane progestins alone and in combination with ethinyl estradiol on serum lipoproteins.
Crona, N; Samsioe, G; Silfverstolpe, G, 1985
)
0.27
" In combination with EE, however, DG seems to be less "anti-oestrogenic" than NORG, as judged from the higher apo-AI and SHBG values after the combination DG + EE compared to those after NORG + EE."( Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol.
Crona, N; Samsioe, G; Silfverstolpe, G, 1984
)
0.27
" In combination with EE, however, DG seems to be less antiestrogenic than NORG, as judged from the higher apo-AI and SHBG values after the combination of DG EE compared to those after NORG & EE."( Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol.
Crona, N; Samsioe, G; Silfverstolpe, G, 1984
)
0.27
"The pharmacokinetics and pharmacodynamics of 150 micrograms desogestrel (DG) or 150 micrograms 3-keto-desogestrel (KDG) in combination with 30 micrograms ethinylestradiol (EE) were compared in a cross-over study."( Prodrug versus drug effects of 150 micrograms desogestrel or 3-keto-desogestrel in combination with 30 micrograms ethinylestradiol on hormonal parameters: relevance of the peak serum level of 3-keto-desogestrel.
Fitzner, M; Jung-Hoffmann, C; Kuhl, H, 1995
)
0.79
"The effect of gestodene 75 micrograms (GTD) versus desogestrel 150 micrograms (DSG) combined with 30 micrograms of ethinylestradiol (EE) on acne lesions and plasma androstenedione (A), total testosterone (T), sex hormone binding globulin (SHBG) and "free androgen index" (FAI) was evaluated in an open study on 19 patients aged 18-35 years affected with postpubertal or persistent non-severe acne vulgaris."( Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
Mango, D; Manna, P; Miggiano, GA; Ricci, S; Serra, GB, 1996
)
0.77
" They aimed to evaluate the effect of GTD and DSG combined with low doses of EE on acne lesions and on hormone levels."( Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
Mango, D; Manna, P; Miggiano, GA; Ricci, S; Serra, GB, 1996
)
0.52
"The effects of a synthetic oral progestogen, desogestrel (DSG), administered with low dose testosterone (T) were investigated to determine the optimal combination for suppression of gonadotropins and spermatogenesis to targets compatible with effective male contraception."( Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism.
Balasubramanian, R; Coelingh-Bennink, HJ; Mulders, TM; Wu, FC, 1999
)
0.78
" The combination with drospirenone had less impact on blood pressure than the combination with desogestrel."( A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.
Buicu, C; Endrikat, J; Gaspard, U; Gerlinger, C; Heithecker, R; Lefebvre, P; Scheen, A, 2003
)
0.74
"The authors examined the changes in the haemostasis during the use of the oral contraceptive combination with 20 microg ethynil estradiol/150 microg desogestrel at 35 women, a basic group, who used the oral contraceptive in the duration of 12 months and a control group (n=35), who do not use the pills."( [Effect of the monophase oral contraceptive combination with 20 ug ethinyl estradiol/150 ug desogestrel on haemostasis].
Markova, D; Milchev, N; Terzhumanov, R; Uchikova, E, 2004
)
0.74
"Three milligrams of DRSP, a progestogen with antimineralocorticoid activity, was combined with either 30 or 20 microg ethinyl estradiol (EE) (DRSP/30EE; DRSP/20EE) and compared with a preparation containing 150 microg desogestrel (DSG) and 30 microg ethinyl estradiol (DSG/30EE)."( A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
Endrikat, J; Gerlinger, C; Heithecker, R; Kluft, C; Mulder, SM, 2006
)
0.71
" This study aimed to investigate MENT implants in combination with etonogestrel on spermatogenesis, gonadotropins, and androgen-dependent tissues in comparison with a testosterone/etonogestrel regimen."( 7alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men.
Anderson, RA; Baird, DT; Kumar, N; Ludlow, H; Walton, MJ,
)
0.13
"To investigate the efficacy, safety, removal characteristics, and x-ray visibility of Nexplanon, a radiopaque etonogestrel contraceptive implant combined with a next-generation applicator."( Nexplanon, a radiopaque etonogestrel implant in combination with a next-generation applicator: 3-year results of a noncomparative multicenter trial.
Blum, GF; Gent, TG; Marintcheva-Petrova, M; Mommers, E; Peters, KP; Sørdal, TS, 2012
)
0.38
"The objective of the study was to evaluate whether treatment with metformin (M) or M combined with oral contraceptive pills (OCPs) resulted in a more advantageous body composition than treatment with OCP alone."( Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome.
Altinok, ML; Andersen, M; Glintborg, D; Hermann, AP; Mumm, H; Ravn, P, 2014
)
0.4
"M treatment alone or in combination with OCP was associated with weight loss and improved body composition compared with OCP, whereas free T levels decreased during M+OCP or OCP."( Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome.
Altinok, ML; Andersen, M; Glintborg, D; Hermann, AP; Mumm, H; Ravn, P, 2014
)
0.4
"To investigate the genetic contribution to this previously observed drug-drug interaction through studying SNPs in genes known to be involved in efavirenz, nevirapine or etonogestrel metabolism in the same group of women."( Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M, 2019
)
0.51
"This study demonstrates the influence of pharmacogenetics on the extent of drug-drug interactions between etonogestrel and efavirenz- or nevirapine-based ART."( Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M, 2019
)
0.51
"To compare the efficacy and the tolerability of letrozole combined with oral contraceptives versus oral contraceptives alone in treating endometriosis-related pain."( Letrozole combined with oral contraceptives versus oral contraceptives alone in the treatment of endometriosis-related pain symptoms: a pilot study.
Luan, X; Wang, Y; Zhao, Y, 2021
)
0.62
"Levonorgestrel containing combination oral products and implants containing levonorgestrel or etonogestrel were prone to CYP3A4-inducing drug-drug interactions that may increase contraceptive failures."( Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system.
Brown, J; Cicali, B; Schmidt, S; Sunaga, T, 2021
)
0.62
"The progestin components of hormonal contraceptives are susceptible to drug-drug interactions, but this susceptibility is influenced by route of administration."( Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system.
Brown, J; Cicali, B; Schmidt, S; Sunaga, T, 2021
)
0.62
" For patients with adenomyosis who refuse surgery and are not candidates for the use of LNG-IUS, an ENG-releasing implant combined with endometrial ablation may be an effective alternative."( Subcutaneous etonogestrel implant combined with endometrial ablation for the treatment of adenomyosis: two case reports.
Cheng, L; Nie, LK; Zhang, PH; Zou, HL, 2022
)
0.72

Bioavailability

Two low-dose oral contraceptives were compared with respect to the relative bioavailability of EE2. Bioavailability of 3-keto-desogestrel averages 76.

ExcerptReferenceRelevance
" Lower bioavailability of KDG (60-80% vs."( Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.
Back, DJ; Kuhnz, W; Power, J; Schütt, B, 1992
)
0.52
" Comparing the relative oral and iv doses, the bioavailability of EE2 (alone) was 59."( The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel.
Back, DJ; Green, S; Orme, M; Ward, S, 1991
)
0.5
"Two low-dose oral contraceptives, both containing the same dose of ethinyl estradiol (EE2) but different progestins (gestodene and desogestrel, respectively), were compared with respect to the relative bioavailability of EE2."( Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of 3 months with two low-dose oral contraceptives in an intraindividual cross-over design.
Back, D; Kuhnz, W; Louton, T; Power, J; Schütt, B, 1991
)
0.49
"Two low-dose oral contraceptives, both containing the same dose of ethinyl estradiol (EE2) but different progestins (gestodene and desogestrel, respectively), were compared with respect to the relative bioavailability of EE2."( Relative bioavailability of ethinyl estradiol from two different oral contraceptive formulations after single oral administration to 18 women in an intraindividual cross-over design.
Gansau, C; Hümpel, M; Kuhnz, W; Louton, T; Schütt, B; Steinberg, B, 1990
)
0.48
" Ethinyl estradiol (mean systemic bioavailability 40% to 50%) is extensively metabolized, principally to a sulfate conjugate."( Gastrointestinal metabolism of contraceptive steroids.
Back, DJ; Madden, S; Orme, ML, 1990
)
0.28
" Bioavailability ranged between 40."( Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel.
Back, DJ; Grimmer, SF; Orme, ML; Shenoy, N, 1987
)
0.56
" Bioavailability was calculated as the ratio of area under the plasma concentration time curve of the oral to the area under the curve of the iv dose."( Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel.
Back, DJ; Grimmer, SF; Orme, ML; Shenoy, N, 1987
)
0.56
" Bioavailability of 3-keto-desogestrel averages 76."( Pharmacokinetics of desogestrel.
Adashi, EY; McClamrock, HD, 1993
)
0.9
" All of these agents are pharmacokinetically similar to older agents: they are highly bioavailable when administered orally, hepatically metabolized, and obtain steady-state concentrations after 8-10 days of continuous administration."( Desogestrel, norgestimate, and gestodene: the newer progestins.
Kaplan, B,
)
1.57
" All of these agents are highly bioavailable when administered orally, hepatically metabolized, and obtain steady-state concentrations after 8-10 days of continuous administration."( Desogestrel, norgestimate, and gestodene: the newer progestins.
Kaplan, B,
)
1.57
" With the use of the highly accurate and specific technique of IDMS it can now be unequivocally established that the different progestins in the tested oral contraceptives have no influence on the bioavailability of EE2 (area under EE2 serum concentration curves, as usually defined in pharmacokinetics)."( Gestodene and desogestrel do not have a different influence on concentration profiles of ethinylestradiol in women taking oral contraceptives--results of isotope dilution mass spectrometry measurements.
Albring, M; Bidlingmaier, F; Brill, K; Siekmann, A; Siekmann, L, 1998
)
0.66
", volume of distribution and clearance, allowing the calculation of the absorption rate and bioavailability of the implant, as a function of time."( Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon.
Huber, J; Schnabel, P; van Beek, A; Wenzl, R, 1998
)
0.3
" The absorption rate of about 30 mcg/day after 3 months of use decreased to 30 mcg/day at the end of 2 years."( Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon.
Huber, J; Schnabel, P; van Beek, A; Wenzl, R, 1998
)
0.3
" Implanon had an absorption rate of almost 60 micrograms/day after 3 months, which slowly decreased to 30 micrograms/day at the end of 2 years."( Pharmacokinetics of Implanon. An integrated analysis.
Huber, J; Wenzl, R, 1998
)
0.3
" In comparison with the DSG/EE COC, the absolute bioavailability for NuvaRing was higher for etonogestrel (102."( Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring.
Mulders, TM; Timmer, CJ, 2000
)
0.31
" This delivery system provides many advantages over oral contraceptives (OCs), including avoidance of the first-pass effect through the liver, constant serum steroid levels, longer duration of use, and greater bioavailability of the hormones."( Contraceptive vaginal rings.
Harwood, B; Mishell, DR, 2001
)
0.31
" Because ENG bioavailability was higher following vaginal administration, the systemic progestogen exposures were comparable with the two contraceptives."( Complete and robust ovulation inhibition with NuvaRing.
Killick, S, 2002
)
0.31
" The effect of progestogens on IGF bioavailability could be an important determinant of the longer-term risks of specific HRT preparations by opposing the potentially beneficial effects of CEE alone on cardiovascular risk."( Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
Anderson, S; Durrington, PN; Gibson, MJ; Heald, A; Kaushal, K; Redpath, M; Selby, PL, 2005
)
0.33
" Because ENG bioavailability was higher following vaginal administration, the systemic progestogen exposures were comparable with the oral contraceptives."( [NuvaRing-combined contraceptive vaginal ring: state of art in 2008. Expert Board of Polish Gynecological Society].
Debski, R; Kotarski, J; Paszkowski, T; Pawelczyk, L; Skrzypulec, V; Tomaszewski, J, 2008
)
0.35
" This analytical method was applied in a relative bioavailability study in order to compare a test budesonide 64 μg/dose nasal spray formulation vs."( Budesonide quantification by HPLC coupled to atmospheric pressure photoionization (APPI) tandem mass spectrometry. Application to a comparative systemic bioavailability of two budesonide formulations in healthy volunteers.
Astigarraga, RB; Borges, BC; Borges, NC; Galvinas, PR; Moreno, RA; Paiva, TR; Sverdloff, CE, 2011
)
0.37
"The EFV-based HAART regimen was associated with a reduction in the bioavailability of ENG, which showed decreases of 63."( Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.
Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; de Souza, RM; Duarte, G; Ferriani, RA; Quintana, SM; Rocha Prandini, TR; Scaranari, C; Vieira, CS, 2014
)
0.4
"The coadministration of EFV decreased the bioavailability of ENG released from the implant, which could impair contraceptive efficacy."( Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.
Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; de Souza, RM; Duarte, G; Ferriani, RA; Quintana, SM; Rocha Prandini, TR; Scaranari, C; Vieira, CS, 2014
)
0.4
" Co-administration with some antiretroviral therapies (ART) changes the bioavailability of the etonogestrel (ENG)-releasing contraceptive implant, possibly affecting the bleeding pattern."( Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy.
Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; Duarte, G; Ferriani, RA; Prandini, TR; Quintana, SM; Ragazini, CS; Vieira, CS, 2016
)
0.43
" There was no statistical difference between bioavailability of ENG treated with DMNs or ID injections (p >0."( Dissolving Microneedles Loaded With Etonogestrel Microcrystal Particles for Intradermal Sustained Delivery.
Gao, Y; He, M; Yang, G; Zhang, S; Zhao, X, 2018
)
0.48
" However, unfavourable bioavailability limits its clinical use."( Contraceptive drugs mitigate experimental stroke-induced brain injury.
Binder, N; El Amki, M; Imthurn, B; Luft, AR; Merki-Feld, GS; Schneider, H; Steffen, R; Wegener, S; Weller, M, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

One-hundred-and-eighty-three women were enrolled in an open, randomized, multicentre study. The present investigation was designed to study the likelihood of the occurrence of any such interaction between the fluoroquinolone antibiotic ciprofloxacin (Ciproxin) and the "low-dose" oral contraceptive Marvelon.

ExcerptRelevanceReference
" Levels of the 3 parameters were unaffected by dosage of the new progestin."( Effect of oral contraceptive containing a new progestin (ORG 2969) on plasma renin activity, growth hormone and immunoreactive insulin.
Erkkola, R; Lammintausta, R; Liukko, P, 1979
)
0.26
" The following difference was found: Women using the lower dosed preparation showed significantly less suppressed FSH values compared to women using Marvelon."( [Clinical experience with Mercilon and Marvelon with special reference to ovarian function].
Huber, PR; Mall-Haefeli, M; Werner-Zodrow, I, 1991
)
0.28
" A further complication is the multiplicity of pharmacological effects elicited by the gestagens and each of these effects is likely to have its own dose-response relationship."( Potency and pharmacokinetics of gestagens.
Fotherby, K, 1990
)
0.28
" Evidence of the vascular complications of oral contraceptives suggests that venous thromboembolism correlates with estrogen dosage and arterial complications with both estrogen and progestogen components."( Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets.
Bonnar, J; Daly, L, 1990
)
0.5
" A dose-response relationship was seen in the endocrine and clinical performance of the CVR."( Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethinylestradiol.
Alapiessa, U; Apter, D; Assendorp, R; Cacciatore, B; Stenman, UH, 1990
)
0.5
"In a study of low-dose oral contraceptives, it was found that the low dosage caused insignificant effects on glucose and lipid metabolism."( Metabolic effects of three new low-dose pills: a six-month experience.
Bertolotto, A; Fioretti, P; Fruzzetti, F; Giampietro, O; Melis, G; Miccoli, R; Navalesi, R; Orlandi, MC; Ricci, C, 1989
)
0.28
" The individual AUCs for 3-keto-desogestrel after dosing with desogestrel (plus EE) or 3-keto-desogestrel (plus EE) show a similar degree of variation."( Serum levels of 3-keto-desogestrel after oral administration of desogestrel and 3-keto-desogestrel.
Bosch, AM; Hasenack, HG; Käär, K, 1986
)
0.87
" Studies of the oral contraceptives in current use show that the coagulation effects depend on the dosage of estrogen and the type of progestogen used in combination."( Coagulation effects of oral contraception.
Bonnar, J, 1987
)
0.27
" The estrogenic activity is shown by the low, even S-E2 levels, but the dosage of E2COA seems to be too low in relation to progestogen dosage."( Ovulation inhibition with 17 beta-estradiol cyclo-octyl acetate and desogestrel.
Cullberg, G; Schubert, W, 1987
)
0.51
" By avoiding the first liver pass the dosage of estrogen can be halved."( Fat-soluble 17 beta-estradiol: a way of reducing dosage in steroid hormonal substitution?
Cullberg, G; Schubert, W, 1988
)
0.27
" High norgestrel dosages caused atrophies of the corpus endometrium significantly more often than low norgestrel dosages, desogestrel or lynestrenol at low dosage levels."( [Dependence of morphologic changes in portio, cervix and endometrium on dosage or potency of synthetic gestagens].
Dallenbach-Hellweg, G; Fenzel, J, 1985
)
0.48
" In contradistinction to other low dosage combination oral contraceptives this new oral contraceptive has a good control of the menstrual cycle."( [Clinical and biochemical results during the treatment with marvelon, a new oral contraceptive (author's transl)].
Huber, P; Mall-Haefeli, M; Weijers, MJ; Werner-Zodrow, I, 1982
)
0.26
" Desogestrel at a dose level used in oral contraceptives did not inhibit the EE-induced increase in SHBG capacity while its influence on this parameter at twice the clinical dosage (0."( Short-term effects of desogestrel and ethinyloestradiol on serum proteins in women.
Käär, K; Rhen, K; Tarkkila, T, 1984
)
1.49
" Protection is ensured with a low drug dosage and no estrogen, and fertility is readily reversible once the implants are removed."( Subdermal contraceptive implants.
Croxatto, H; Diaz, S; Peralta, O, 1995
)
0.29
" Even though the low dosage of ethinyl estradiol (20 mcg) may have contributed to the prevention of bone mass loss, it could not achieve the peak bone mass."( Bone mass and long-term monophasic oral contraceptive treatment in young women.
Filippa, N; Gallina, D; Nappi, RE; Perotti, F; Polatti, F, 1995
)
0.29
"To evaluate the clinical and hormonal response of the antiandrogen flutamide (Eulexin, Schering Plough, Milan, SA, Italy) associated with a low dosage oral contraceptive (OC) in a group of hirsute women who were unresponsive to OC treatment."( Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients.
Aglianò, A; Cianci, A; Ciotta, L; Marletta, E; Palumbo, G; Pisana, L, 1994
)
0.29
"After 8 months treatment with flutamide and low dosage OC, the Ferriman-Gallwey score improved in all patients, mean values decreasing from 25."( Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients.
Aglianò, A; Cianci, A; Ciotta, L; Marletta, E; Palumbo, G; Pisana, L, 1994
)
0.29
"Flutamide, associated with low dosage OC, favorably influence the hirsutism in PCOD women who are unresponsive to OC treatment alone."( Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients.
Aglianò, A; Cianci, A; Ciotta, L; Marletta, E; Palumbo, G; Pisana, L, 1994
)
0.29
" The serum concentrations of KDG and gestodene during multiple dosing cannot be predicted on the basis of single dose pharmacokinetics."( Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives.
Back, DJ; Daume, E; Hammerstein, J; Neiss, A; Power, J; Schindler, AE; Simon, A; Winkler, U, 1993
)
0.54
" The dosage schedule was 7/7/7, that is, a different dose for each 7-day period."( Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol.
Archer, DF; Lammers, P; Timmer, CJ, 1994
)
0.53
" The present investigation was designed to study the likelihood of the occurrence of any such interaction between the fluoroquinolone antibiotic ciprofloxacin (Ciproxin) at a dosage of 500 mg twice a day and the "low-dose" oral contraceptive Marvelon (30 microgram of ethinyl estradiol [EE] plus 150 microgram of desogestrel)."( No interaction between ciprofloxacin and an oral contraceptive.
Droppert, RM; Hoepelman, IM; Moesker, HL; Nauta, JJ; Scholten, PC; Zwinkels, MG, 1998
)
0.47
"Among new forms of hormonal contraception, three interesting exemples are described with a high level of effectiveness and low dosage regimen that allow improved safety and tolerance: a very low-dose estrogen-progestogen combination of ethinylestradiol and gestodene for 24-day cyclical administration; a progestogen-alone subcutaneous implant containing etonogestrel; and a levonorgestrel-releasing intrauterine system."( [New forms of hormonal contraception].
Buicu, C; Gaspard, U; van den Brûle, F, 2000
)
0.31
" Testosterone concentrations fell slightly during treatment with evidence of a linear dosage effect."( Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men.
Anderson, RA; Baird, DT; Everington, D; Groome, NP; Martin, CW; Riemersma, RA; Riley, SC, 2000
)
0.6
" Subsequently, the single-dose pharmacokinetic parameters of etonogestrel from Cerazette tablets were compared with those after multiple dosing of one Cerazette tablet once daily for 7 days, in a subgroup of 12 subjects (study part 2)."( Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette and Liseta.
Cohen, AF; Dieben, TO; Srivastava, N; Timmer, CJ,
)
0.36
" The dosed radioactivity was predominantly ( approximately 60%) excreted via urine, while about 35% was excreted via the feces."( Excretion and metabolism of desogestrel in healthy postmenopausal women.
Gloudemans, RH; Groothuis, GM; Peeters, PA; Rietjens, IM; van Lier, JJ; Verheggen, FT; Verhoeven, CH; Vos, RM, 2001
)
0.6
" Different formulations of miconazole nitrate and single as well as multiple dosing were investigated during two separate randomized, open-label, crossover studies."( The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication.
Dieben, TO; Mulders, TM; van den Heuvel, MW; Verhoeven, CH, 2004
)
0.32
" Results demonstrated that the combined dosage regimen could damage epididymal sperm motility and density, and induce infertility within 8 weeks in rats; the infertility could be consistently sustained by giving single GA (12."( Combined administration of low-dose gossypol acetic acid with desogestrel/mini-dose ethinylestradiol/testosterone undecanoate as an oral contraceptive for men.
Cui, GH; Guo, Y; Xue, SP; Yang, ZJ; Ye, WS, 2004
)
0.56
" We believe that the observed reduction in the number of bleeding days by almost 50% compared to placebo in both the mifepristone combination group and the doxycycline group demonstrates a clinically significant improvement in bleeding patterns and that further trials are needed to compare different combinations of therapy as well as multiple dosing regimens in order to establish which is the most effective treatment option."( A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon.
Findlay, JK; Fraser, IS; Hickey, M; O'Connor, V; Palmer, D; Salamonsen, LA; Weisberg, E, 2006
)
0.33
" Several new contraceptive methods with alternate routes of delivery and less frequent dosing are available."( The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring.
Arias, RD; Nucatola, DL; Wagner, MS, 2007
)
0.34
"The contraceptive vaginal ring offers effective contraception that is self-administered, requires less frequent dosing than many other forms of contraception, and provides low doses of hormones."( The contraceptive vaginal ring.
Edwardson, J; Jamshidi, R, 2010
)
0.36
"5 mg×kg(-1)×d(-1)) was given; group H, the same dosage of DSG/EE/TU as in group GH were administered; group C, rats were treated with vehicle (1% methyl cellulose) as control."( Drug synergistic antifertility effect of combined administration of low-dose gossypol with steroid hormones in rats.
Chang, Q; Hei, CC; Liu, Z; Ma, WZ; Qian, XJ; Shen, XS; Xu, ZL, 2011
)
0.37
"To determine whether extended-cycle dosing of an ultralow dose vaginal ring contraceptive decreases frequency of migraine aura and prevents menstrual related migraine (MRM)."( The impact of extended-cycle vaginal ring contraception on migraine aura: a retrospective case series.
Calhoun, A; Ford, S; Pruitt, A, 2012
)
0.38
" With the evolution of increasingly lower dosed combined hormonal contraceptives, we now have formulations that--provided that ovulation is inhibited--result in lower peak levels of estrogen than the concentrations attained during the native menstrual cycle."( The impact of extended-cycle vaginal ring contraception on migraine aura: a retrospective case series.
Calhoun, A; Ford, S; Pruitt, A, 2012
)
0.38
" An Arrhenius relationship of the zero-order release constants was established, indicating that temperature is a valid parameter to accelerate drug release from this dosage form and that the release mechanism is maintained under these accelerated test conditions."( Investigating the feasibility of temperature-controlled accelerated drug release testing for an intravaginal ring.
Clark, MR; Externbrink, A; Friend, DR; Klein, S, 2013
)
0.39
"Ormeloxifene with its convenient twice-weekly dosage schedule was effective in treating AUB-L, with 72% of patients responding to 6-month treatment compared with 8% with COC, even though leiomyoma volume increased insignificantly with both ormeloxifene and COCs."( Efficacy of ormeloxifene versus oral contraceptive in the management of abnormal uterine bleeding due to uterine leiomyoma.
Agarwal, N; Bhatla, N; Hari, S; Kachhawa, G; Kriplani, A; Kulshrestha, V; Srivastava, A, 2016
)
0.43
"Combined contraceptive vaginal rings (CVR) are increasingly appreciated due to several beneficial properties like avoidance of the hepatic first-pass effect, a comparatively low dosage of hormones and comfortable use."( Safety, efficacy and quality of life of the novel vaginal contraceptive ring containing etonogestrel/ethinylestradiol 11.0/3.474 mg after 3 years of "real life" experience.
Colli, E; Müller, A; Regidor, PA; Sailer, M, 2020
)
0.56
"Assessment of estrus cyclicity indicated a dose-response relationship in the shift to a larger number of acyclic rats and longer in duration spent in the diestrus phase."( A rodent model of human dose-equivalent progestin-only implantable contraception.
Allaway, HCM; Bloomfield, SA; Invik, J; Pierson, RA, 2021
)
0.62
" Our aim was to describe the effectiveness and safety of both dosing strategies in our clinic cohort to help guide future management."( Double-Dose Desogestrel: Is it Effective in Adolescent Menstrual Dysfunction?
Burton, RC; Williams, CE, 2021
)
1
"Prevalence of amenorrhea and light spotting, side effects, and discontinuation rates of both dosing regimens."( Double-Dose Desogestrel: Is it Effective in Adolescent Menstrual Dysfunction?
Burton, RC; Williams, CE, 2021
)
1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
contraceptive drugA chemical substance that prevents or reduces the probability of conception.
progestinA synthetic progestogen.
synthetic oral contraceptiveAn oral contraceptive which owes its effectiveness to synthetic preparation.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
17beta-hydroxy steroidA 17-hydroxy steroid in which the hydroxy group at position 17 has a beta-configuration.
terminal acetylenic compoundAn acetylenic compound which a carbon of the C#C moiety is attached to a hydrogen atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency25.11890.031637.5844354.8130AID504865
AR proteinHomo sapiens (human)Potency7.38100.000221.22318,912.5098AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency26.62610.000214.376460.0339AID720691; AID720692; AID720719
pregnane X nuclear receptorHomo sapiens (human)Potency5.62340.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency7.78300.000229.305416,493.5996AID743069; AID743075; AID743077; AID743079; AID743080
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency31.62280.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency22.71840.000323.4451159.6830AID743065; AID743067
gemininHomo sapiens (human)Potency13.33590.004611.374133.4983AID624296
Cellular tumor antigen p53Homo sapiens (human)Potency33.49150.002319.595674.0614AID651631; AID720552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sex hormone-binding globulinHomo sapiens (human)Kd0.25120.00020.34964.7863AID318680
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
androgen bindingSex hormone-binding globulinHomo sapiens (human)
protein bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingSex hormone-binding globulinHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
extracellular regionSex hormone-binding globulinHomo sapiens (human)
extracellular exosomeSex hormone-binding globulinHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1053264Antagonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as inhibition of agonist-induced cAMP accumulation at 100 uM preincubated for 10 mins prior to agonist addition measured after 30 mins by HTRF assay relative t2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID318680Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID1053262Agonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin at 100 uM by luminometric analysis relative to quinpirol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1053266Agonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 100 uM after 30 mins by HTRF assay relative to SKF812972013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1053260Antagonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin assessed as inhibition of agonist-induced effect at 50 uM after 15 mins by luminometric analysis relative to haloperidol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,572)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990140 (8.91)18.7374
1990's379 (24.11)18.2507
2000's448 (28.50)29.6817
2010's479 (30.47)24.3611
2020's126 (8.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 100.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index100.98 (24.57)
Research Supply Index7.66 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index189.19 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (100.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials495 (30.35%)5.53%
Reviews192 (11.77%)6.00%
Case Studies146 (8.95%)4.05%
Observational19 (1.16%)0.25%
Other779 (47.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (59)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Observation of Compliance With Dosage in Women Using Oral Contraceptives Designed for the Non Stop Use, (it Means 28 Pills for 28-days Cycle). [NCT01185678]8,416 participants (Actual)Observational2010-05-31Completed
A Multicenter, Open Label, Randomized, Two-period Crossover Study on the Insertion of MK-8342A (NuvaRing®) Placebo With and Without the Use of NuvaRing Applicator in Healthy Female Subjects [NCT02275546]Phase 3164 participants (Actual)Interventional2014-12-11Completed
A Randomized, Double-Blind, Parallel Group, Bioequivalence Study of IMPLANON and Radiopaque IMPLANON [NCT00620464]Phase 3108 participants (Actual)Interventional2005-05-31Completed
[NCT01256619]Phase 261 participants (Anticipated)Interventional2010-09-30Recruiting
Drug Use Investigation of MARVELON [NCT01005056]3,838 participants (Actual)Observational2005-05-31Completed
A Randomized, Multicenter, Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Doses of an Etonogestrel-releasing Medicated Intrauterine System (ENG-MIUS) Versus a Copper-releasing Intrauterine Device (IUD) [NCT00967746]Phase 284 participants (Actual)Interventional2009-11-30Completed
The Effectiveness of Cyclic Desogestrel Therapy for Abnormal Uterine Bleeding Associated With Anovulation: a Non-inferiority Double Blinded Randomized Control Trial [NCT02103764]Phase 3160 participants (Anticipated)Interventional2013-08-31Active, not recruiting
Validation of 24-hour Trough Concentration as a Surrogate for Intensive Pharmacokinetic Measurements for a Combined Oral Contraceptive Pill Containing Desogestrel [NCT05002738]Phase 422 participants (Actual)Interventional2021-09-10Completed
Phase 4 Study Comparison of Two Combined Oral Contraceptive Regimens and an Intravaginal Hormonal Ring Against Placebo for Management of Bleeding Problems in Women Using Implanon, the Sub-dermal Contraceptive Implant [NCT01384331]Phase 4200 participants (Anticipated)Interventional2011-07-31Not yet recruiting
A Multi-centre, Randomized, Double-blind, Active Control, Parallel-group, 2-arm Study to Investigate the Effect of Ethinylestradiol / Drospirenone (0.02 mg/3 mg) Oral Contraception in a 24/4 Regimen Compared to Ethinylestradiol / Desogestrel (0.02 mg/0.15 [NCT01076582]Phase 3592 participants (Actual)Interventional2010-04-30Completed
Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study [NCT05227456]Phase 297 participants (Anticipated)Interventional2022-07-01Recruiting
Bioavailability of a Formulation of Desogestrel 0.075 mg Coated Tablets With Regards to the Marketed Reference Product [NCT04422028]Phase 130 participants (Actual)Interventional2020-01-11Completed
Predictors of Abnormal Uterine Bleeding in Progestin-only Contraceptives Users [NCT03398811]390 participants (Actual)Observational2018-08-01Completed
A Randomized, Open-Label Clinical Trial to Identify Predictive Factors for Controlled Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH in GnRH Antagonist Regimen With or Without Oral Contraceptive Scheduling [NCT00778999]Phase 4442 participants (Actual)Interventional2006-10-01Completed
A Multicenter, Open-Label Study to Evaluate Ovarian Follicular Activity and Hormone Levels With the Oral Contraceptive Regimen DR-102 Compared to Two 28-day Oral Contraceptive Regimens Containing Different Synthetic Progestins [NCT01291004]Phase 1206 participants (Actual)Interventional2011-01-31Completed
Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa for Ovarian Stimulation in Donors [NCT03354494]40 participants (Actual)Observational2016-01-31Completed
Assessment of Desogestrel for a Pharmacological Recovery of Ventilatory Activity in Congenital Central Hypoventilation Syndrome - Ondine Syndrome [NCT01243697]Phase 2/Phase 36 participants (Actual)Interventional2011-04-30Completed
A Phase 1 Clinical Trial to Evaluate the Pharmacokinetics, Removability, Safety, and Tolerability of Casea S Contraceptive Implants [NCT05174884]Phase 130 participants (Anticipated)Interventional2023-11-30Not yet recruiting
Evaluation of Female Sexual Functions in Progestogen-only Contraceptive Users [NCT02579590]444 participants (Actual)Observational2017-05-01Completed
Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome [NCT01500473]Phase 21 participants (Actual)Interventional2012-02-29Terminated(stopped due to Only one subject was studied, who did not respond.)
The Impact of Different Administration Routes of Hormonal Contraceptives on Androgen Synthesis, Glucose Metabolism and Inflammation. A Prospective Randomized Trial. [NCT01087879]45 participants (Anticipated)Interventional2007-10-31Completed
Clinical and Systematic Biology Study of Traditional Chinese Medicine, Western Medicine and Low-level Light Therapy for Primary [NCT03953716]Phase 4480 participants (Anticipated)Interventional2019-06-22Recruiting
A Prospective Observational Clinical Trial to Compare the Effect of Immediate Postpartum Nexplanon Placement Versus Standard Postpartum Contraceptive Care on Consistent Contraceptive Use and Rapid Repeat Pregnancy in Opioid Dependent Women. [NCT02657148]200 participants (Actual)Observational2016-05-31Completed
Desogestrel and Corifollitropin Treatment for Ovarian Stimulation in Donors [NCT02757287]Phase 40 participants (Actual)Interventional2016-05-31Withdrawn(stopped due to Lack of financial support)
Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing® [NCT00710606]40 participants (Actual)Interventional2008-06-30Completed
The Effects of Oral vs. Intravaginal Hormonal Contraception on Vaginal Health [NCT00612508]14 participants (Actual)Interventional2007-05-31Completed
A Feasibility Study Into the Contraceptive Effect of Estetrol Alone or Combined With Either Progesterone or Desogestrel by Daily Oral Administration to Healthy Female Volunteers for 28 Days. [NCT00563472]Phase 252 participants (Actual)Interventional2007-11-30Completed
The Effect of 30mcg and Levonorgestrel 150 Combined Oral Contraceptive, Etonogestrel-releasing Subdermal Implant and Levonorgestrel-releasing Intrauterine System on Breast-Milk Production and Infant Growth in Fully Breast-Feeding Women [NCT01388582]Phase 440 participants (Actual)Interventional2011-04-30Completed
A Prospective, Multicenter, Randomized, Double-Blind Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With the Oral Contraceptive Regimen DR-1021 [NCT00544882]Phase 361 participants (Actual)Interventional2007-10-31Completed
A Comparison Between Corifollitropin Alfa and Recombinant FSH for Follicular Recruitment in Women With Polycystic Ovaries Who Undergo IVM Treatment [NCT03197077]Phase 3145 participants (Actual)Interventional2017-11-01Completed
Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women Protocol: WHIRL-07-2971 [NCT00565240]41 participants (Actual)Interventional2007-11-30Completed
Follicular Profiles After Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle [NCT00204438]45 participants Interventional2002-02-28Completed
A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of a 91-Day Extended Cycle Oral Contraceptive Regimen, Compared to Two 28-day Standard Oral Contraceptive Regimens, on Hemostatic Parameters in Healthy Women. [NCT01252186]Phase 2265 participants (Actual)Interventional2010-11-30Completed
A Comparative Efficacy of Low-dose Combine Oral Contraceptives Containing Desogestrel 150 mg and Drospirenone 3 mg on Premenstrual Symptoms [NCT01482338]Phase 490 participants (Actual)Interventional2011-06-30Completed
Continuous Versus Cyclic Use of an Oral Contraceptive Pills in Adolescents [NCT00326404]Phase 3130 participants (Anticipated)Interventional2006-05-31Recruiting
Desogestrel Versus GnRH Antagonist (Ganirelix) in IVF/ICSI Patients Undergoing Ovarian Stimulation: a Randomized Controlled Trial [NCT04728659]Phase 4165 participants (Anticipated)Interventional2020-10-01Recruiting
Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes [NCT00946192]Phase 3121 participants (Actual)Interventional2009-05-31Completed
The Frequency and Management of Breakthrough Bleeding During Extended Therapy With the Transvaginal Contraceptive Ring [NCT00475553]75 participants (Actual)Interventional2006-05-31Completed
Quantification of Immune Cells in Women Using Contraception [NCT01873170]326 participants (Actual)Observational2013-08-31Completed
Randomized Controlled Trial of Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant [NCT00847587]Phase 469 participants (Actual)Interventional2009-01-31Completed
An Open-Label, Randomised, Parallel-Group Comparison to Investigate the Efficacy of Yasmin® (30 µg Ethinylestradiol, 3mg Drospirenone) and Marvelon® (30 µg Ethinylestradiol, 150 µg Desogestrel) on Cycle Control in Healthy Chinese Women Over 13 Cycles [NCT00185419]Phase 3842 participants (Actual)Interventional2003-11-30Completed
Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin [NCT01738724]Phase 414 participants (Actual)Interventional2012-01-31Terminated(stopped due to PI went for a post-doc course and when he came back he moved for another job)
PPOS and CFA for Elective Freeze-all Ovarian Stimulation Cycles: a Prospective Cross-over Study [NCT06175832]Phase 460 participants (Anticipated)Interventional2024-01-01Not yet recruiting
Generating Evidence to Improve Same-day Etonogestrel (ENG) Implant Insertion for Emergency Contraception [NCT06162611]Phase 4790 participants (Anticipated)Interventional2023-11-06Recruiting
A Randomized Study to Evaluate the Predictive Impact of Using Cerazette Progestin Only Pill Before Nexplanon Insertion Regarding Bleeding Pattern [NCT01438736]Phase 490 participants (Anticipated)Interventional2011-09-30Not yet recruiting
Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women [NCT00828542]40 participants (Actual)Interventional2007-07-31Completed
A Prospective Double Blind Randomized Controlled Trial to Study the Effectiveness of a Desogestrel for the Treatment of Pelvic Pain or Dysmenorrhea in the Patients Undergone Conservative Surgery for Pelvic Endometriosis [NCT01559480]40 participants (Actual)Interventional2012-01-31Completed
The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS). [NCT01588873]Phase 442 participants (Anticipated)Interventional2012-04-30Recruiting
A Randomized Controlled Trial of NuvaRing® Versus Combined Oral Contraceptive Pills for Pre-treatment in In-Vitro Fertilization (IVF) Cycles [NCT01298128]70 participants (Actual)Interventional2006-02-28Terminated
The Use of Oral Desogestrel for the Preoperative Treatment of Endometrioma Compared With Placebo : A Randomized Controlled Trial Evaluation of the Effect on Cyst Diameter and Associated Pain [NCT04941833]Phase 2/Phase 320 participants (Actual)Interventional2021-06-01Completed
Rates of Contraceptive Failure When Unprotected Intercourse Has Occurred 6-14 Days Prior to Contraceptive Initiation [NCT02076217]1,030 participants (Anticipated)Observational2014-02-28Active, not recruiting
Safety and Acceptability of Vaginal Rings That Protect Women From Unintended Pregnancy [NCT01796613]Phase 2/Phase 3120 participants (Actual)Interventional2013-06-30Completed
Immediate vs. Delayed Insertion of Nexplanon After Termination of Pregnancy Over 14-weeks Gestation (NAPA) [NCT02037919]150 participants (Actual)Interventional2014-06-30Active, not recruiting
Comparative Study of the Effect on Acne With Norgestimate Containing Triphasic Oral Contraceptive and Biphasic Preparation Containing Desogestrel [NCT01466673]Phase 4201 participants (Actual)Interventional2008-12-31Completed
Labor and Delivery Implant Insertion: A Randomized Controlled Trial [NCT02866643]Phase 395 participants (Actual)Interventional2016-10-28Completed
A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of DR-102 Compared to a 28-day Standard Oral Contraceptive Regimen, on Hemosatic Parameters in Healthy Women [NCT01388491]Phase 2293 participants (Actual)Interventional2011-10-31Completed
Can a Three Months Treatment With Oral Desogestrel Prior to Insertion of the Etonogestrel Subdermal Implant Improve Continuation Rate at One Year? [NCT05174195]67 participants (Actual)Interventional2016-08-15Terminated(stopped due to difficult recruitment)
Open-label, Randomized, Fixed Sequence Cross-over Study With Five Parallel Treatment Arms and Three Treatment Periods to Quantify the Drug-drug Interactions of Two Rifampicin Dose Strengths on Four Progestins and a Fixed Progestin-ethinylestradiol Combina [NCT03353857]Phase 168 participants (Actual)Interventional2017-11-29Completed
Feasibility and Efficacy of a New Ovarian Stimulation Regimen With RANDom Start, Use of Corifollitropin Alpha and Progestin Protocol for Oocyte donorS [NCT03895099]Phase 3110 participants (Actual)Interventional2020-09-04Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00544882 (9) [back to overview]Percentage of Participants With Bleeding or Spotting During Unscheduled and Scheduled Study Periods
NCT00544882 (9) [back to overview]Change From Cycle 2 Days 1 - 20 to Cycle 2 Days 21 - 28 in Maximum Follicle Size
NCT00544882 (9) [back to overview]Number of Days of Bleeding During Unscheduled and Scheduled Study Periods
NCT00544882 (9) [back to overview]Number of Days of Bleeding or Spotting During Unscheduled and Scheduled Study Periods
NCT00544882 (9) [back to overview]Percentage of Follicles Greater Than 5 mm in Diameter
NCT00544882 (9) [back to overview]Percentage of Participants With Bleeding During Unscheduled and Scheduled Study Periods
NCT00544882 (9) [back to overview]Serum Estradiol Levels by Cycle Day
NCT00544882 (9) [back to overview]Serum Follicle Stimulating Hormone (FSH) Levels by Cycle Day
NCT00544882 (9) [back to overview]Serum Inhibin-B Levels by Cycle Day
NCT00612508 (2) [back to overview]Adverse Events
NCT00612508 (2) [back to overview]Thickness of the Vaginal Epithelium (in mm)With Means and Standard Deviations Reported.
NCT00620464 (2) [back to overview]Bioequivalence of Implanon® and Radiopaque Implanon
NCT00620464 (2) [back to overview]Bioequivalence of Implanon® and Radiopaque Implanon.
NCT00710606 (3) [back to overview]Mean Endometrial Proliferation
NCT00710606 (3) [back to overview]Number of Participants Achieving a Maximum Follicle Diameter > 13mm During the 3 Weeks of Follow-up
NCT00710606 (3) [back to overview]Mean Serum Concentrations of Etonogestrel and Ethinyl Estradiol
NCT00778999 (1) [back to overview]Total Number of Oocytes
NCT00828542 (1) [back to overview]Etonogestrel-releasing Contraceptive Subdermal Implant Inserted During the Immediate Puerperium Effects on the Hemostatic System of Healthy Women Over a Period of Twelve Weeks
NCT00847587 (2) [back to overview]Time to Lactogenesis Stage II
NCT00847587 (2) [back to overview]Crematocrit of Human Milk
NCT00946192 (2) [back to overview]Change in Total Volumetric Bone Mineral Density (Tibia)
NCT00946192 (2) [back to overview]Change in Lumbar Bone Mineral Density
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Activated Partial Thromboplastin Time (APTT) Based Activated Protein-C Resistance (APC)
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Antithrombin
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Corticosteroid Binding Globulin
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in D-dimer
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Endogenous Thrombin Potential (EPT) Based Activated Protein-C Resistance (APC)
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Factor II
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Factor VII
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Factor VIII
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Fibrinogen
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Free Protein S
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Plasmin-Antiplasmin (PAP) Complex
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Plasminogen
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Protein C Activity
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Protein C Antigen
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Prothrombin Fragment 1+2 Levels
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Sex Hormone Binding Globulin (SHBG)
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Thyroid Stimulating Hormone (TSH)
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Tissue Factor Pathway Inhibitor (TFPI)
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Tissue Plasminogen Activator (t-PA)
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Total Cortisol
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Total Protein S
NCT01298128 (1) [back to overview]Incidence of Side Effects of Oral Contraceptives Such as Abnormal Bleeding, Headache, Breast Discomfort, Bloating and Mood Swings (See Description)
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in D-Dimer
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Period in Protein S Total Antigen
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Activated Partial Thromboplastin Time (APTT)-Based Activated Protein-C (APC) Resistance
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Antithrombin
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Corticosteroid-Binding Globulin
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Thyroid-Stimulating Hormone (TSH)
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Endogenous Thrombin Potential (EPT)-Based Activated Protein-C (APC) Resistance
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor II Activity
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VII
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VIII
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Protein C Activity
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Prothrombin Fragment 1 + 2 Levels
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Serum Random Total Cortisol
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Sex Hormone Binding Globulin
NCT01466673 (10) [back to overview]Change From Baseline in Blood Pressure (BP) at Month 6
NCT01466673 (10) [back to overview]Change From Baseline in Body Weight at Month 6
NCT01466673 (10) [back to overview]Change From Baseline in Total and Each Type of Acne Lesions Count at Month 1
NCT01466673 (10) [back to overview]Change From Baseline in Total and Each Type of Acne Lesions Count at Month 3
NCT01466673 (10) [back to overview]Change From Baseline in Total and Each Type of Acne Lesions Count at Month 6
NCT01466673 (10) [back to overview]Number of Participants Non-Compliant With Therapy
NCT01466673 (10) [back to overview]Number of Participants With Abnormal Vaginal Blood Loss at Month 1, 3 and 6
NCT01466673 (10) [back to overview]Number of Participants With Treatment Response at the End-of-Therapy by Participant's Self-Assessment at Month 6
NCT01466673 (10) [back to overview]Percentage of Participants Showing Treatment Response on the Investigator's Global Assessment at Month 6
NCT01466673 (10) [back to overview]Percentage of Participants With Categorical Score for Sebum Assessment at Month 1, 3 and 6
NCT01500473 (3) [back to overview]Time Maintained Ventilation Off Mechanical Ventilation During Sleep.
NCT01500473 (3) [back to overview]Hypoxic Ventilatory Response
NCT01500473 (3) [back to overview]Hypercapnic Ventilatory Response
NCT02275546 (2) [back to overview]Percentage of Participants With Successful Ring Insertion
NCT02275546 (2) [back to overview]Percentage of Participants With Vaginal Ring Expulsion Within 48 Hours of Insertion
NCT02866643 (6) [back to overview]Time to Lactogenesis Stage II [Questionnaire]
NCT02866643 (6) [back to overview]Number of of Participants Actively Breastfeeding
NCT02866643 (6) [back to overview]Number of Participants Attending a Postpartum Care Visit by Month 3
NCT02866643 (6) [back to overview]Number of Participants Satisfied or Very Satisfied With Implant Contraceptive
NCT02866643 (6) [back to overview]Number of Participants Still With the Contraceptive Implant at Month 12.
NCT02866643 (6) [back to overview]Number of Participants Reporting a Pregnancy Within 12 Months

Percentage of Participants With Bleeding or Spotting During Unscheduled and Scheduled Study Periods

The percentage of participants with unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding or spotting was derived from participant diaries. (NCT00544882)
Timeframe: Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21

,
Interventionpercentage of participants (Number)
Cycle 2 - Unscheduled (Day 1-21)Cycle 2 - Scheduled (Day 22-28)Cycle 3 - Unscheduled (Day 1-21)
DR-102148.177.855.6
Mircette59.392.653.6

[back to top]

Change From Cycle 2 Days 1 - 20 to Cycle 2 Days 21 - 28 in Maximum Follicle Size

The change in the size of the largest documented follicle during combination therapy (Days 1 to 21) and during monotherapy/placebo (Days 21-28) measured by trans-vaginal ultrasound. (NCT00544882)
Timeframe: Cycle 2, Days 1-20 and Cycle 2, Days 21-28

Interventionmm (Mean)
DR-1021-2.02
Mircette-1.79

[back to top]

Number of Days of Bleeding During Unscheduled and Scheduled Study Periods

The total number of days of unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding (not including spotting) was derived from participant diaries. (NCT00544882)
Timeframe: Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21

,
Interventiondays (Mean)
Cycle 2 - Unscheduled (Day 1-21)Cycle 2 - Scheduled (Day 22-28)Cycle 3 - Unscheduled (Day 1-21)
DR-10210.702.300.70
Mircette0.522.630.71

[back to top]

Number of Days of Bleeding or Spotting During Unscheduled and Scheduled Study Periods

The total number of days of unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding or spotting was derived from participant diaries. (NCT00544882)
Timeframe: Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21

,
Interventiondays (Mean)
Cycle 2 - Unscheduled (Day 1-21)Cycle 2 - Scheduled (Day 22-28)Cycle 3 - Unscheduled (Day 1-21)
DR-10212.193.191.96
Mircette1.413.671.64

[back to top]

Percentage of Follicles Greater Than 5 mm in Diameter

Ovarian follicles were measured by trans-vaginal ultrasound. The size of the 3 largest follicles was documented for each participant, and the percentage of follicles greater than 5 mm in diameter was calculated based on the total number follicles present (indicated by n for each time point). (NCT00544882)
Timeframe: Cycle 1, Days 11, 19-20, 23, 25, 27, Cycle 2, Days 4, 11, 19-20, 23, 25, 27, Cycle 3, Day 4.

,
Interventionpercentage of follicles (Number)
Cycle 1 - Day 11 (n=63, 48)Cycle 1 - Day 19-20 (n= 47, 94)Cycle 1 - Day 23 (n= 30, 76)Cycle 1 - Day 25 (n= 85, 106)Cycle 1 - Day 27 (n=135, 145)Cycle 2 - Day 4 (n=154, 156)Cycle 2 - Day 11 (n=76, 54)Cycle 2 - Days 19-20 (n=143, 148)Cycle 2 - Day 23 (n=91, 62)Cycle 2 - Day 25 (n=69, 80)Cycle 2 - Day 27 (n=94, 132)Cycle 3 - Day 4 (n=138, 117)
DR-102130.229.850.032.929.635.127.617.524.230.423.425.4
Mircette29.227.726.331.135.231.431.518.924.218.820.527.4

[back to top]

Percentage of Participants With Bleeding During Unscheduled and Scheduled Study Periods

The percentage of participants with unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding (not including spotting) was derived from participant diaries. (NCT00544882)
Timeframe: Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21

,
Interventionpercentage of participants (Number)
Cycle 2 - Unscheduled (Day 1-21)Cycle 2 - Scheduled (Day 22-28)Cycle 3 - Unscheduled (Day 1-21)
DR-102118.577.829.6
Mircette33.377.825.0

[back to top]

Serum Estradiol Levels by Cycle Day

Levels of estradiol were measured throughout the study from blood samples. (NCT00544882)
Timeframe: Cycle 2, Day 2 (Baseline), and Days 4, 6, 19-20, 23, 24, 25, 27, 28, Cycle 3, Days 2, 4 and 6.

,
Interventionpg/mL (Median)
Cycle 2 - Day 2 (n=28, 28)Cycle 2 - Day 4 (n=28, 28)Cycle 2 - Day 6 (n=27, 27)Cycle 2 - Days 19-20 (n=26, 28)Cycle 2 - Day 23 (n=27, 28)Cycle 2 - Day 24 (n=25, 28)Cycle 2 - Day 25 (n=27, 28)Cycle 2 - Day 27 (n=25, 28)Cycle 2 - Day 28 (n=26, 28)Cycle 3 - Day 2 (n=27, 28)Cycle 3 - Day 4 (n=27, 27)Cycle 3 - Day 6 (n=24, 26)
DR-102147.0062.5043.0019.0024.0025.0024.0030.0036.0034.0066.0028.50
Mircette51.5034.5029.0020.5019.0026.5026.0020.0027.5043.0027.0032.00

[back to top]

Serum Follicle Stimulating Hormone (FSH) Levels by Cycle Day

Levels of follicle stimulating hormone were measured throughout the study from blood samples. (NCT00544882)
Timeframe: Cycle 2, Day 2 (Baseline), and Days 4, 6, 19-20, 23, 24, 25, 27, 28, Cycle 3, Days 2, 4 and 6.

,
InterventionmIU/mL (Median)
Cycle 2 - Day 2 (n=28, 28)Cycle 2 - Day 4 (n=28, 28)Cycle 2 - Day 6 (n=28, 27)Cycle 2 - Days 19-20 (n=26, 28)Cycle 2 - Day 23 (n=27, 28)Cycle 2 - Day 24 (n=25, 28)Cycle 2 - Day 25 (n=27, 28)Cycle 2 - Day 27 (n=25, 28)Cycle 2 - Day 28 (n=26, 28)Cycle 3 - Day 2 (n=27, 28)Cycle 3 - Day 4 (n=27, 28)Cycle 3 - Day 6 (n=24, 26)
DR-10214.003.553.701.452.702.802.903.705.054.903.702.50
Mircette4.003.703.501.552.353.703.903.904.704.053.602.50

[back to top]

Serum Inhibin-B Levels by Cycle Day

Levels of inhibin-B were measured throughout the study from blood samples. (NCT00544882)
Timeframe: Cycle 2, Day 2 (Baseline), and Days 4, 6, 19-20, 23, 24, 25, 27, 28, Cycle 3, Days 2, 4 and 6.

,
Interventionpg/mL (Median)
Cycle 2 - Day 2 (n=28, 28)Cycle 2 - Day 4 (n=28, 28)Cycle 2 - Day 6 (n=28, 27)Cycle 2 - Days 19-20 (n=26, 28)Cycle 2 - Day 23 (n=27, 28)Cycle 2 - Day 24 (n=25, 28)Cycle 2 - Day 25 (n=27, 28)Cycle 2 - Day 27 (n=25, 28)Cycle 2 - Day 28 (n=26, 28)Cycle 3 - Day 2 (n=27, 28)Cycle 3 - Day 4 (n=27, 28)Cycle 3 - Day 6 (n=24, 26)
DR-102192.3042.8046.3523.1528.1036.8035.2039.6041.9554.7051.1036.15
Mircette99.0064.4541.2028.8532.1555.0062.3049.2055.0557.9552.2529.55

[back to top]

Adverse Events

Self-reported treatment-related and serious adverse events (NCT00612508)
Timeframe: over 168 days

Interventionparticipants (Number)
Oral Contraceptive1
Intravaginal Ring Contraceptive0

[back to top]

Thickness of the Vaginal Epithelium (in mm)With Means and Standard Deviations Reported.

Histologic evalation of vaginal sections was performed to measured and record the absolute thickness of the vaginal epithelium. Baseline findings were compared to biopsies after three and six cycles of treatment. Mean values were compared using T-test for paired data for baseline and 84 days, and baseline and 168 days (NCT00612508)
Timeframe: baseline, 84 days, 168 days

,
Interventionmm (Mean)
mean difference at 84 daysmean difference at 168 days
Desogen0.01-0.02
NuvaRing-0.005.007

[back to top]

Bioequivalence of Implanon® and Radiopaque Implanon

"Bioequivalence testing was performed based on serum etonogestrel Cmax. Bioequivalence was to be concluded when the 90% confidence limits of Cmax were fully contained within the acceptance range of 0.80-1.25.~Cmax (pg/mL): Peak concentration." (NCT00620464)
Timeframe: 3 years

Interventionpg/mL (Mean)
Radiopaque Implanon (ro Imp)1200
Implanon (Imp)1145

[back to top]

Bioequivalence of Implanon® and Radiopaque Implanon.

"Bioequivalence testing was performed based on serum etonogestrel AUC0-6months, AUC0-24months, and AUC0-36months. Bioequivalence was to be concluded when the 90% confidence limits of AUC0-6months, AUC0-24months, and AUC0-36months were fully contained within the acceptance range of 0.80-1.25.~AUC0-6months (Area under the curve from zero to six months).~AUC0-24months (Area under the curve from zero to 24 months).~AUC0-36months (Area under the curve from zero to 36 months)." (NCT00620464)
Timeframe: 3 years

,
Interventionpg•month/mL (Mean)
AUC (0-6 months) (n=46 ro imp; n=46 imp)AUC (0-24 months) (n=37 ro imp; n=32 imp)AUC (0-36 months) (n=32 ro imp; n=30 imp)
Implanon (Imp)229061317819
Radiopaque Implanon (ro Imp)229659547667

[back to top]

Mean Endometrial Proliferation

The mean endometrial proliferation from week 1, week 2 and week3 (NCT00710606)
Timeframe: Transvaginal ultrasound measurements of endometrial proliferation will be completed over continuous ring use, an average of 3 weeks

Interventionmillimeters (Mean)
Obese Subjects4.7
Normal Weight Subjects3.9

[back to top]

Number of Participants Achieving a Maximum Follicle Diameter > 13mm During the 3 Weeks of Follow-up

Follicular development was minimal in both groups, with only five women achieving a maximum follicle diameter > 13mm at any time during the 3 weeks of follow-up (3 normal weight and 2 obese women). (NCT00710606)
Timeframe: continuous ring use, an average of 3 weeks

InterventionParticipant w/follicular diameter >=13mm (Number)
Obese Subjects2
Normal Weight Subjects3

[back to top]

Mean Serum Concentrations of Etonogestrel and Ethinyl Estradiol

Serum concentrations were obtained from thirty-seven women completed follow-up. (NCT00710606)
Timeframe: Measurements at Week 3 and Week 6 continuous ring use

,
Interventionng/L (Geometric Mean)
Etonogesterel (ENG) Week 3Ethinyl Estradiol (EE) Week 3Etonogesterel (ENG) Week 6Ethinyl Estradiol (EE) Week 6
Normal Weight127521.9106316.2
Obese124014.8109612.5

[back to top]

Total Number of Oocytes

The total number of oocytes on the Day of oocyte pick-up is an indication of ovarian response (NCT00778999)
Timeframe: 12 weeks

InterventionNumber of oocytes (Mean)
Oral Contraceptive12.4
Non-Oral Contraceptive12.1

[back to top]

Etonogestrel-releasing Contraceptive Subdermal Implant Inserted During the Immediate Puerperium Effects on the Hemostatic System of Healthy Women Over a Period of Twelve Weeks

"Activated protein C (APC) resistance is the most important marker of coagulation system in women using hormonal contraceptive methods.~APC resistance was determined by testing the effect of APC on the endogenous thrombin potential (ETP) using the Calibrated Automated Thrombogram® (CAT) assay. The sensitivity ratio or APC (APCsr) of each plasma sample was determined in the presence or absence of approximately 4 nM APC (Enzyme Research Laboratories, Swansea, United Kingdom). The APC concentration was adjusted to maintain the residual thrombin generation activity in normal pooled plasma at approximately 10%. Normal pooled plasma was run in parallel on each plate.~The normalized ratio (nAPCsr) was determined by dividing the APCsr of an individual sample by the APCsr of the pooled plasma.~Thus, nAPCsr >1.0 indicated APC resistance." (NCT00828542)
Timeframe: 12 weeks

Interventionratio (Mean)
Etonogestrel Implant5.9
Depot Medroxyprogesterone5.5

[back to top]

Time to Lactogenesis Stage II

"The primary outcome, time to lactogenesis stage II in hours, was documented by maternal perception as previously described and validated in the literature. Subjects were asked, Has your milk come in? Some women experience this as a prickly feeling or tingling in the breast, dripping from the other nipple when nursing, milk running from the baby's mouth, or gulping by the baby. If the response was positive, subjects were then asked, When did your milk come in? and the response recorded to the nearest hour." (NCT00847587)
Timeframe: 5 days postpartum

Interventionhours (Mean)
Early Postpartum Insertion64.3
Standard Postpartum Insertion65.2

[back to top]

Crematocrit of Human Milk

Determination of creamatocrit is a simple method for estimating the fat & energy content of human milk based on the centrifugation of milk in a hematocrit centrifuge. The method for creamatocrit measurement was as described by Lucas et al (LucasA, GibbsJA, LysterRL, BaumJD. Creamatocrit: simple clinical technique for estimating fat concentration and energy value of human milk. BritMedJnl1978;1:1018-20)using a standard hematocrit centrifuge, standard hematocrit glass capillary tube, & vernier calipers. Measurements were performed in duplicate and the mean for each measurement used for analysis. (NCT00847587)
Timeframe: 6 weeks postpartum

InterventionPercent creamatocrit (Mean)
Early Postpartum Insertion7.5
Standard Postpartum Insertion6.8

[back to top]

Change in Total Volumetric Bone Mineral Density (Tibia)

Change in total volumetric bone density at the tibia with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes (NCT00946192)
Timeframe: 12 months

Interventionmg HA/cm^3 (Mean)
Estrogen Patch7.01
Estrogen Pill1.17
Control3.71

[back to top]

Change in Lumbar Bone Mineral Density

Change in bone density with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes (NCT00946192)
Timeframe: 12 months

Interventiong/cm^2 (Mean)
Estrogen Patch0.025
Estrogen Pill0.008
Control0.012

[back to top]

Change From Baseline to End of Month 6 in Activated Partial Thromboplastin Time (APTT) Based Activated Protein-C Resistance (APC)

"The APC resistance assay is a clotting test that measures the ratio of APTT clotting times in the presence and absence of a standard amount of exogenous APC. APC resistance is calculated as the ratio of the clotting time after APC addition over the clotting time with no APC addition.~APC resistance is defined as a poor anticoagulant response of plasma to APC (minimal prolongation of the APTT) and a correspondingly low ratio." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionratio (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive-0.12
28-day Levonorgestrel Oral Contraceptive-0.15
28-day Desogestrel Oral Contraceptive-0.27

[back to top]

Change From Baseline to End of Month 6 in Antithrombin

"Antithrombin is a protein in the blood that naturally blocks blood clots from forming.~Results are reported as a percent of the amount expected in normal plasma. By definition, the mean value in normal plasma is 100%. The reference range is approximately 80% to 130%.for adults." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive2.36
28-day Levonorgestrel Oral Contraceptive-0.05
28-day Desogestrel Oral Contraceptive-0.83

[back to top]

Change From Baseline to End of Month 6 in Corticosteroid Binding Globulin

(NCT01252186)
Timeframe: Baseline to Month 6

Interventionnmol/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive576.33
28-day Levonorgestrel Oral Contraceptive563.85
28-day Desogestrel Oral Contraceptive634.64

[back to top]

Change From Baseline to End of Month 6 in D-dimer

D-dimer is the degradation product of cross-linked fibrin and is a marker of thrombin and fibrin formation and turnover. (NCT01252186)
Timeframe: Baseline to Month 6

Interventionng/mL (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive86.74
28-day Levonorgestrel Oral Contraceptive72.43
28-day Desogestrel Oral Contraceptive158.05

[back to top]

Change From Baseline to End of Month 6 in Endogenous Thrombin Potential (EPT) Based Activated Protein-C Resistance (APC)

"This assay is based on measurement of the effect of activated protein C on the endogenous thrombin potential, the time integral of thrombin generation initiated in plasma through the extrinsic coagulation pathway.~The APC resistance assay measures the ratio of endogenous thrombin potential in the presence and absence of a standard amount of exogenous APC.~APC resistance is calculated as the ratio of EPT after APC addition over the EPT with no APC addition.~APC resistance is defined as a poor anticoagulant response of plasma to APC (less inhibition of thrombin formation) and a correspondingly higher ratio." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionratio (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive0.38
28-day Levonorgestrel Oral Contraceptive0.37
28-day Desogestrel Oral Contraceptive0.57

[back to top]

Change From Baseline to End of Month 6 in Factor II

Clotting factor II, also called prothrombin, functions in blood coagulation. Results are reported as percent of normal plasma concentrations. By definition, normal plasma contains 100% (1 unit/mL) of each factor. The reference range is approximately 60% to 140% for adults. (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive6.89
28-day Levonorgestrel Oral Contraceptive7.98
28-day Desogestrel Oral Contraceptive8.57

[back to top]

Change From Baseline to End of Month 6 in Factor VII

"Clotting factor VII, also called proconvertin or autoprothrombin I, functions in blood coagulation.~Results are reported as percent of normal plasma concentrations. By definition, normal plasma contains 100% (1 unit/mL) of each factor. The reference range is approximately 60% to 140% for adults." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive14.27
28-day Levonorgestrel Oral Contraceptive22.98
28-day Desogestrel Oral Contraceptive43.22

[back to top]

Change From Baseline to End of Month 6 in Factor VIII

"Clotting factor VIII, also known as anti-hemophilic factor (AHF), functions in blood coagulation by stabilizing fibrin clots.~Results are reported as a percent of the amount expected in normal plasma. By definition, the mean value in normal plasma is 100%. The reference range is approximately 70% to 140%.for adults." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive-3.23
28-day Levonorgestrel Oral Contraceptive0.08
28-day Desogestrel Oral Contraceptive5.53

[back to top]

Change From Baseline to End of Month 6 in Fibrinogen

Fibrinogen (factor I) is a glycoprotein that helps in the formation of blood clots. (NCT01252186)
Timeframe: Baseline to Month 6

Interventiong/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive0.12
28-day Levonorgestrel Oral Contraceptive0.22
28-day Desogestrel Oral Contraceptive-0.04

[back to top]

Change From Baseline to End of Month 6 in Free Protein S

"Protein S helps to regulate blood clot formation. Protein S exists in two forms: a free form and a complex form. Free protein S combines with Protein C to degrade coagulation factors VIIIa and Va, slowing down the generation of new thrombin and inhibiting further clotting.~Results are reported as a percent of the amount expected in normal plasma. By definition, the mean value in normal plasma is 100%. The reference range is approximately 70% to 140%; lower for women than for men." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive2.96
28-day Levonorgestrel Oral Contraceptive4.62
28-day Desogestrel Oral Contraceptive-18.2

[back to top]

Change From Baseline to End of Month 6 in Plasmin-Antiplasmin (PAP) Complex

The plasmin-antiplasmin (PAP) complex is a marker of thrombin and fibrin formation and turnover. (NCT01252186)
Timeframe: Baseline to Month 6

Interventionng/mL (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive10.72
28-day Levonorgestrel Oral Contraceptive-6.42
28-day Desogestrel Oral Contraceptive107.81

[back to top]

Change From Baseline to End of Month 6 in Plasminogen

Plasminogen is the precursor of plasmin, which lyses fibrin clots. (NCT01252186)
Timeframe: Baseline to Month 6

Interventiong/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive0.04
28-day Levonorgestrel Oral Contraceptive0.04
28-day Desogestrel Oral Contraceptive0.04

[back to top]

Change From Baseline to End of Month 6 in Protein C Activity

"Protein C helps to regulate blood clot formation. Activated Protein C (APC) combines with Protein S (a cofactor) to degrade coagulation factors VIIIa and Va, slowing down the generation of new thrombin and inhibiting further clotting.~Results are reported as a percent of the amount expected in normal plasma. By definition, the mean value in normal plasma is 100%. The reference range is approximately 70% to 140% for adults." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive-6.15
28-day Levonorgestrel Oral Contraceptive-4.39
28-day Desogestrel Oral Contraceptive-2.41

[back to top]

Change From Baseline to End of Month 6 in Protein C Antigen

"Protein C helps to regulate blood clot formation. Activated Protein C (APC) combines with Protein S (a cofactor) to degrade coagulation factors VIIIa and Va, slowing down the generation of new thrombin and inhibiting further clotting.~Results are reported as a percent of the amount expected in normal plasma. By definition, the mean value in normal plasma is 100%. The reference range is approximately 70% to 140% in adults." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive12.83
28-day Levonorgestrel Oral Contraceptive11.97
28-day Desogestrel Oral Contraceptive10.00

[back to top]

Change From Baseline to End of Month 6 in Prothrombin Fragment 1+2 Levels

Prothrombin fragment 1+2 is a coagulation factor, released when prothrombin is cleaved by activated factor X. Elevated plasma levels of prothrombin fragment 1+2 indicate high risk of thrombosis. (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpmol/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive169.53
28-day Levonorgestrel Oral Contraceptive157.99
28-day Desogestrel Oral Contraceptive592.29

[back to top]

Change From Baseline to End of Month 6 in Sex Hormone Binding Globulin (SHBG)

(NCT01252186)
Timeframe: Baseline to Month 6

InterventionmIU/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive34.87
28-day Levonorgestrel Oral Contraceptive30.85
28-day Desogestrel Oral Contraceptive165.01

[back to top]

Change From Baseline to End of Month 6 in Thyroid Stimulating Hormone (TSH)

(NCT01252186)
Timeframe: Baseline top Month 6

InterventionmIU/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive-0.22
28-day Levonorgestrel Oral Contraceptive0.10
28-day Desogestrel Oral Contraceptive0.22

[back to top]

Change From Baseline to End of Month 6 in Tissue Factor Pathway Inhibitor (TFPI)

Tissue Factor Pathway Inhibitor (TFPI) is an anti-coagulation protein that binds to activated protein X. (NCT01252186)
Timeframe: Baseline to Month 6

Interventionng/mL (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive4.65
28-day Levonorgestrel Oral Contraceptive2.54
28-day Desogestrel Oral Contraceptive-1.34

[back to top]

Change From Baseline to End of Month 6 in Tissue Plasminogen Activator (t-PA)

Tissue plasminogen activator catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for the breakdown of blood clots. (NCT01252186)
Timeframe: Baseline to Month 6

Interventionµg/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive-0.91
28-day Levonorgestrel Oral Contraceptive-1.48
28-day Desogestrel Oral Contraceptive-9.3

[back to top]

Change From Baseline to End of Month 6 in Total Cortisol

(NCT01252186)
Timeframe: Baseline to Month 6

Interventionnmol/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive217.94
28-day Levonorgestrel Oral Contraceptive262.40
28-day Desogestrel Oral Contraceptive227.68

[back to top]

Change From Baseline to End of Month 6 in Total Protein S

"Protein S helps to regulate blood clot formation. Protein S exists in two forms: a free form and a complex form. Free protein S combines with activated protein C to degrade coagulation factors VIIIa and Va, slowing down the generation of new thrombin and inhibiting further clotting.~Results are reported as a percent of the amount expected in normal plasma. By definition, the mean value in normal plasma is 100%. The reference range is approximately 70% to 140%; lower for women than for men." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive-11.06
28-day Levonorgestrel Oral Contraceptive-11.48
28-day Desogestrel Oral Contraceptive-21.59

[back to top]

Incidence of Side Effects of Oral Contraceptives Such as Abnormal Bleeding, Headache, Breast Discomfort, Bloating and Mood Swings (See Description)

abnormal bleeding, intermittent bleeding, headache, breast discomfort, bloating, mood swings, nausea, vaginal discharge, vomitting, weight gain (NCT01298128)
Timeframe: patients were followed for the duration of an in-vitro fertilization cycle- 2 months

Interventionparticipants (Number)
NuvaRing3
Combined Oral Contraceptive Pill4

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in D-Dimer

Normal range for this hemostatic parameter was 0 to 729 mcg/L. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionmcg/L (Least Squares Mean)
Treatment I: (DR-102)16.4
Treatment II13.4

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Period in Protein S Total Antigen

The normal range for this hemostatic parameter was 50% to 147%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionpercentage of normal 50% to 147% (Least Squares Mean)
Treatment I: (DR-102)-11.4
Treatment II-6.6

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Activated Partial Thromboplastin Time (APTT)-Based Activated Protein-C (APC) Resistance

This hemostatic parameter is calculated by dividing the clotting time with APC by the clotting time without APC. Normal range for this measure was defined as a ratio of 2.00 to 3.36. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionratio (Least Squares Mean)
Treatment I: (DR-102)-0.3
Treatment II-0.4

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Antithrombin

Normal range for this hemostatic parameter was 75% to 130%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionpercentage of normal (Least Squares Mean)
Treatment I: (DR-102)-1.6
Treatment II-3.2

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Corticosteroid-Binding Globulin

Normal range for this adrenal parameter was 1906.448 to 4520.504 mg/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionmg/L (Least Squares Mean)
Treatment I: (DR-102)4083.3
Treatment II3721.8

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Thyroid-Stimulating Hormone (TSH)

Normal range for this parameter was 0.35 to 5.5 mIU/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

InterventionmIU/L (Least Squares Mean)
Treatment I: (DR-102)0.2
Treatment II0.3

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Endogenous Thrombin Potential (EPT)-Based Activated Protein-C (APC) Resistance

This hemostatic parameter is calculated by dividing the clotting time with APC by the clotting time without APC. Normal range for this measure was defined as a ratio of 0.32 to 1.79. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionratio (Least Squares Mean)
Treatment I: (DR-102)0.8
Treatment II0.7

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor II Activity

Normal range for this hemostatic parameter was 70% to 150%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionpercentage of normal (Least Squares Mean)
Treatment I: (DR-102)3.3
Treatment II3.0

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VII

Normal range for this hemostatic parameter was 60% to 150%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionpercentage of normal (Least Squares Mean)
Treatment I: (DR-102)17.9
Treatment II15.1

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VIII

Normal range for this hemostatic parameter was 50% to 180%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionpercentage of normal (Least Squares Mean)
Treatment I: (DR-102)11.1
Treatment II10.6

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Protein C Activity

The normal range for this hemostatic parameter was 70% to 180%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionpercentage of normal (Least Squares Mean)
Treatment I: (DR-102)16.3
Treatment II13.0

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Prothrombin Fragment 1 + 2 Levels

Normal range for this hemostatic parameter was 41 to 372 pmol/L. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionpmol/L (Least Squares Mean)
Treatment I: (DR-102)45.0
Treatment II56.8

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Serum Random Total Cortisol

Normal range for this adrenal parameter was 85.6 to 618.2 nmol/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionnmol/L (Least Squares Mean)
Treatment I: (DR-102)239.0
Treatment II230.8

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Sex Hormone Binding Globulin

Normal range for this parameter was 28 to 146 nmol/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionnmol/L (Least Squares Mean)
Treatment I: (DR-102)163.4
Treatment II149.1

[back to top]

Change From Baseline in Blood Pressure (BP) at Month 6

Blood pressure is the pressure of blood flowing through blood vessels. Change from Baseline in blood pressure is the value at Month 6 minus value at Baseline. (NCT01466673)
Timeframe: Baseline and Month 6

,
InterventionMillimeters of Mercury (Mean)
Systolic BP: Baseline (n=100/101)Diastolic BP: Baseline (n=100/101)Systolic BP: Change at Month 6 (n=93, 95)Diastolic BP: Change at Month 6 (n=93, 95)
Ethinyl Estradiol/Desogestrel (EE/DSG)110.269.47-0.24-0.48
Ethinyl Estradiol/Norgestimate (EE/NGM)110.670.230.33-0.80

[back to top]

Change From Baseline in Body Weight at Month 6

Change from Baseline in body weight is the value at Month 6 minus value at Baseline. (NCT01466673)
Timeframe: Baseline and Month 6

,
InterventionKilograms (Mean)
Baseline (n=100,101)Change at Month 6 (n=93,95)
Ethinyl Estradiol/Desogestrel (EE/DSG)54.24-0.20
Ethinyl Estradiol/Norgestimate (EE/NGM)55.62-0.08

[back to top]

Change From Baseline in Total and Each Type of Acne Lesions Count at Month 1

Total acne (pimples) lesion (abnormal area of tissue, such as a wound, sore, rash, or boil) count is summation of all lesions which includes all comedones (open and closed), papules, pustules, and nodules. Change from Baseline means lesions at Baseline minus lesions at Month 1. Positive value indicates decrease in lesion count while negative value indicates increase in lesion count. (NCT01466673)
Timeframe: Baseline and Month 1

,
InterventionLesions (Mean)
Comedones Counts: BaselinePapules Counts: BaselinePustules Counts: BaselineNodules Counts: BaselineTotal Counts: BaselineComedones Counts: Change at Month 1Papules Counts: Change at Month 1Pustules Counts: Change at Month 1Nodules Counts: Change at Month 1Total Counts: Change at Month 1
Ethinyl Estradiol/Desogestrel (EE/DSG)11.434.461.120.0017.003.440.620.18-0.024.22
Ethinyl Estradiol/Norgestimate (EE/NGM)10.974.320.900.1216.313.430.200.350.124.10

[back to top]

Change From Baseline in Total and Each Type of Acne Lesions Count at Month 3

Total acne (pimples) lesion (abnormal area of tissue, such as a wound, sore, rash, or boil) count is summation of all lesions which includes all comedones (open and closed), papules, pustules, and nodules. Change from Baseline means lesions at Baseline minus lesions at Month 3. Positive value indicates decrease in lesion count while negative value indicates increase in lesion count. (NCT01466673)
Timeframe: Baseline and Month 3

,
InterventionLesions (Mean)
Comedones Counts: Change at Month 3 (n=93, 96)Papules Counts: Change at Month 3 (n=93, 96)Pustules Counts: Change at Month 3 (n=93, 96)Nodules Counts: Change at Month 3 (n=93, 96)Total Counts: Change at Month 3 (n=93, 96)
Ethinyl Estradiol/Desogestrel (EE/DSG)5.601.890.700.008.19
Ethinyl Estradiol/Norgestimate (EE/NGM)5.712.830.630.128.84

[back to top]

Change From Baseline in Total and Each Type of Acne Lesions Count at Month 6

Total acne (pimples) lesion (abnormal area of tissue, such as a wound, sore, rash, or boil) count is summation of all lesions which includes all comedones (open and closed), papules, pustules, and nodules. Change from Baseline means lesions at Baseline minus lesions at Month 6. Positive value indicates decrease in lesion count while negative value indicates increase in lesion count. (NCT01466673)
Timeframe: Baseline and Month 6

,
InterventionLesions (Mean)
Comedones Counts: Change at Month 6 (n=93, 95)Papules Counts: Change at Month 6 (n=93, 95)Pustules Counts: Change at Month 6 (n=93, 95)Nodules Counts: Change at Month 6 (n=93, 95)Total Counts: Change at Month 6 (n=93, 95)
Ethinyl Estradiol/Desogestrel (EE/DSG)8.212.770.960.0011.94
Ethinyl Estradiol/Norgestimate (EE/NGM)9.023.520.770.1313.44

[back to top]

Number of Participants Non-Compliant With Therapy

Compliance was assessed by transforming the data of forgotten tablets listed in the diary cards. Number of participants who forgot to take the drug was reported. (NCT01466673)
Timeframe: Month 1, 3 and 6

,
InterventionParticipants (Number)
At Month 1 (n=100, 101)At Month 3 (n=93, 96)At Month 6 (n=93, 95)
Ethinyl Estradiol/Desogestrel (EE/DSG)5106
Ethinyl Estradiol/Norgestimate (EE/NGM)71310

[back to top]

Number of Participants With Abnormal Vaginal Blood Loss at Month 1, 3 and 6

Vaginal blood loss encompasses spotting and bleeding. Spotting is defined as a bleeding requiring no or at most one sanitary pad per day; however, bleeding requires two or more sanitary pads per day. (NCT01466673)
Timeframe: Month 1, 3 and 6

,
InterventionParticipants (Number)
Spotting at Month 1 (n=100,101)Spotting at Month 3 (n=93, 96)Spotting at Month 6 (n=93, 95)Bleeding at Month 1 (n=100,101)Bleeding at Month 3 (n=93, 96)Bleeding at Month 6 (n=93, 95)
Ethinyl Estradiol/Desogestrel (EE/DSG)243473
Ethinyl Estradiol/Norgestimate (EE/NGM)5641346

[back to top]

Number of Participants With Treatment Response at the End-of-Therapy by Participant's Self-Assessment at Month 6

Participant's self-assessment at end-of-therapy was measured by using the self-assessment questionnaire which included 3 questions, about the rating of acne improvement since start of study; comparison of this acne treatment with the one used in past and the continuity of treatment on physician's prescription to evaluate efficacy and acceptability of the study medication. The score was graded at 4 parameters as excellent, better, no change and worse. (NCT01466673)
Timeframe: Month 6

,
InterventionParticipants (Number)
ExcellentBetterNo ChangeWorse
Ethinyl Estradiol/Desogestrel (EE/DSG)355831
Ethinyl Estradiol/Norgestimate (EE/NGM)474534

[back to top]

Percentage of Participants Showing Treatment Response on the Investigator's Global Assessment at Month 6

Percentage of participants showing treatment response on the Investigator's global assessment was graded on a 5-point scale as 0=worse, 1=no change, 2=fair, 3=good, and 4=excellent. (NCT01466673)
Timeframe: Month 6

,
InterventionPercentage of participants (Number)
0 (Worse)1 (No Change)2 (Fair)3 (Good)4 (Excellent)
Ethinyl Estradiol/Desogestrel (EE/DSG)1.031.0323.7152.5821.65
Ethinyl Estradiol/Norgestimate (EE/NGM)5.054.044.0443.4343.43

[back to top]

Percentage of Participants With Categorical Score for Sebum Assessment at Month 1, 3 and 6

Sebum assessment that is facial seborrhea (very oily skin) was assessed using sebutape strip on the forehead. Percentage of participants with facial seborrhea were assessed using categorical scores ranging from level 1 (lowest) to level 5 (highest). Highest level indicates worsening. (NCT01466673)
Timeframe: Baseline and Month 1, 3 and 6

,
InterventionPercentage of Participants (Number)
Level 1: Baseline (n=100,101)Level 2: Baseline (n=100,101)Level 3: Baseline (n=100,101)Level 4: Baseline (n=100,101)Level 5: Baseline (n=100,101)Level 1: Month 1 (n=100,101)Level 2: Month 1 (n=100,101)Level 3: Month 1 (n=100,101)Level 4: Month 1 (n=100,101)Level 5: Month 1 (n=100,101)Level 1: Month 3 (n=93, 96)Level 2: Month 3 (n=93, 96)Level 3: Month 3 (n=93, 96)Level 4: Month 3 (n=93, 96)Level 5: Month 3 (n=93, 96)Level 1: Month 6 (n=93, 95)Level 2: Month 6 (n=93, 95)Level 3: Month 6 (n=93, 95)Level 4: Month 6 (n=93, 95)Level 5: Month 6 (n=93, 95)
Ethinyl Estradiol/Desogestrel (EE/DSG)3.9612.8744.5534.653.968.9111.8845.5432.670.9910.4214.5859.3814.581.0422.1143.1629.475.260.00
Ethinyl Estradiol/Norgestimate (EE/NGM)3.0010.0043.0031.0013.007.0013.0047.0030.003.006.4534.4145.1611.832.1544.0927.9620.436.451.08

[back to top]

Time Maintained Ventilation Off Mechanical Ventilation During Sleep.

length of time the subject could breathe adequately spontaneously until SpO2 fell below 80% and or PetCO2 rose above 65 mmHg. (NCT01500473)
Timeframe: 3 weeks

Interventionseconds (Number)
Females With CCHS > 16 Years Old on Desogestrel89

[back to top]

Hypoxic Ventilatory Response

Increase in minute ventilation as oxygen saturation of hemoglobin falls. (NCT01500473)
Timeframe: 3 weeks

Interventionsubjects with positive response (Number)
Females With CCHS > 16 Years Old on Desogetrel0

[back to top]

Hypercapnic Ventilatory Response

Increase in ventilation with increasing partial pressure of CO2 (NCT01500473)
Timeframe: 3 weeks

Interventionliters per minute/ mmHg PCO2 (Number)
Females With CCHS > 16 Years Old on Desogestrel-0.520

[back to top]

Percentage of Participants With Successful Ring Insertion

Participants completed a Post-Insertion Questionnaire in which they were asked about their experience inserting the vaginal ring. Their answers were recorded and evaluated. (NCT02275546)
Timeframe: Day 1 (immediately after vaginal ring insertion)

InterventionPercentage of participants (Number)
Applicator100
No Applicator (Manual)100

[back to top]

Percentage of Participants With Vaginal Ring Expulsion Within 48 Hours of Insertion

Participants completed a Follow-Up Questionnaire in which they asked if they experienced vaginal ring expulsion. Their answers were recorded and evaluated. (NCT02275546)
Timeframe: Up to 48 hours after vaginal ring insertion

InterventionPercentage of participants (Number)
Applicator0
No Applicator (Manual)0

[back to top]

Time to Lactogenesis Stage II [Questionnaire]

"Lactogenesis Stage II: The initiation of copious milk secretion as documented by maternal perception.~To obtain measurement of time to lactogenesis, we will document time at which participants perceive initiation of copious milk secretion using a set of specific validated questions and subtract this by the documented time of delivery." (NCT02866643)
Timeframe: Participants will be monitored daily by the research staff, in the first seven days postpartum, or until lactogenesis reported, beginning at 24-hours following delivery, to determine time to lactogenesis stage II.

Interventionhours (Mean)
Delivery Room Insertion65
Postpartum Insertion67.5

[back to top]

Number of of Participants Actively Breastfeeding

Exclusive breastfeeding means feedling with breast milk only. Any breast feeding means feeding with breast milk, with water and/or formula. (NCT02866643)
Timeframe: 2 weeks, 4 weeks, 3 months, 6 months, and 12 months after delivery

,
InterventionParticipants (Count of Participants)
Exclusive - week 2Exclusive - week 4Exclusive - month 3Exclusive - month 6Any - week 2Any - week 4Any - month 3Any - month 6Any - month 12
Delivery Room Insertion131097251718135
Postpartum Insertion16863272220137

[back to top]

Number of Participants Attending a Postpartum Care Visit by Month 3

(NCT02866643)
Timeframe: month 3

InterventionParticipants (Count of Participants)
Delivery Room Insertion17
Postpartum Insertion24

[back to top]

Number of Participants Satisfied or Very Satisfied With Implant Contraceptive

Participant-rated as very satisfied, satisfied, neither satisfied or dissatisfied, dissatisfied, or very dissatisfied. (NCT02866643)
Timeframe: month 12

InterventionParticipants (Count of Participants)
Delivery Room Insertion16
Postpartum Insertion10

[back to top]

Number of Participants Still With the Contraceptive Implant at Month 12.

(NCT02866643)
Timeframe: month 12

InterventionParticipants (Count of Participants)
Delivery Room Insertion14
Postpartum Insertion12

[back to top]

Number of Participants Reporting a Pregnancy Within 12 Months

(NCT02866643)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Delivery Room Insertion1
Postpartum Insertion1

[back to top]